Methods of using substituted tetralins and indanes

ABSTRACT

The invention features tetralin and indane compounds, compositions containing them, and methods of using them as PPAR alpha modulators to treat or inhibit the progression of, for example, diabetes.

CROSS-REFERENCES TO RELATED APPLICATIONS

[0001] This application is a non-provisional patent application of U.S.provisional patent application No. 60/420,026 filed on Oct. 21, 2002 andU.S. provisional patent application No. 60/495,788 filed on Aug. 15,2003 entitled, “METHODS OF USING SUBSTITUTED TETRALINS AND INDANES”.

FIELD OF THE INVENTION

[0002] The invention features substituted tetralin and indanederivatives, compositions containing them, and methods of using them.

BACKGROUND

[0003] A member of the nuclear receptor family, a group ofligand-activated transcription factors, the peroxisomeproliferator-activated receptor alpha (PPAR alpha) is a necessarytranscription factor regulating genes relating to fatty acid metabolismand insulin action.

[0004] PPAR alpha receptors are found predominantly in the liver. Thegenes regulated by PPAR alpha include enzymes involved in thebeta-oxidation of fatty acids, the liver fatty acid transport protein,and apo Al, an important component of high density lipoproteins (HDL).Selective, high affinity PPAR alpha agonists increase hepatic fatty acidoxidation, which in turn decreases circulating triglycerides and freefatty acids. The reduction of circulating triglycerides may mediate theobserved decrease, or improvement, in insulin resistance in insulinresistant or diabetic animals when treated with PPAR alpha agonists.Such treatment in animal obesity models is associated with weight loss.Known as treatments for hyperlipidemia, fibrates are weak PPAR alphaagonists.

[0005] Examples of known PPAR alpha agonists variously useful forhyperlipidemia, diabetes, or atherosclerosis include fibrates such asfenofibrate (Fournier), gemfibrozil (Parke-Davis/Pfizer, Mylan, Watson),clofibrate (Wyeth-Ayerst, Novopharm), bezafibrate, and ciprofibrate andureidofibrates such as GW 7647, GW 9578, and GW 9820 (GlaxoSmithKline).Known PPAR alpha/gamma dual agonists useful as insulin sensitizersinclude ragaglitazar (Novo Nordisk), tesaglitazar (AstraZeneca), and GW409544 (GlaxoSmithKline/Ligand Pharmaceuticals).

SUMMARY

[0006] The invention features compounds of formula (I) below:

[0007] or a pharmaceutically acceptable salt, C₁₋₆ ester or C₁₋₆ amidethereof wherein

[0008] each of R₁ and R₂ is independently H, C₁₋₆ alkyl, (CH₂)_(m)NR_(a)R_(b), (CH₂)_(m)OR₈, (CH₂)_(m)NH(C4O)R₈, or (CH₂)_(m)CO₂R₈, whereeach of R_(a), R_(b), and R₈ is independently H or C₁₋₆ alkyl, or R₁ andR₂ taken together with the carbon atom to which they are attached are aC₃₋₇ cycloalkyl;

[0009] m is between 1 and 6;

[0010] n is 1 or 2;

[0011] X is O or S; wherein X is at the 5 or 6 position when n is 1; andwherein X is at the 6 or 7 position when n is 2;

[0012] R₃ is H, phenyl, C₁₋₃ alkoxy, C₁₋₃ alkylthio, halo, cyano, C₁₋₆alkyl, nitro, NR₉R₁₀, NHCOR₁₀, CONHR₁₀; and COOR₁₀; and R₃ is ortho ormeta to X;

[0013] R₄ is H or —(C₁₋₅ alkylene)R₁₅, where R₁₅ is H, C₁₋₇ alkyl,[di(C₁₋₂ alkyl)amino](C₁₋₆ alkylene), (C₁₋₃ alkoxyacyl)(C₁₋₆ alkylene),C₁₋₆ alkoxy, C₃₋₇ alkenyl, or C₃₋₈ alkynyl, wherein R₄ has no more than9 carbon atoms; R₄ can also be —(C₁₋₅ alkylene)R₁₅ wherein R₁₅ is C₃₋₆cycloalkyl, phenyl, phenyl-O—, phenyl-S—, or a 5-6 membered heterocyclylwith between 1 and 2 heteroatoms selected from N, O, and S;

[0014] Y is NH, NH—CH₂, or O;

[0015] each of R₅ and R₇ is independently selected from H, C₁₋₆ alkyl,halo, cyano, nitro, COR₁₁, COOR₁₁, C₁₋₄ alkoxy, C₁₋₄ alkylthio, hydroxy,phenyl, NR₁₁R₁₂ and 5-6 membered heterocyclyl with between 1 and 2heteroatoms selected from N, O, and S;

[0016] R₆ is selected from C₁₋₆ alkyl, halo, cyano, nitro, COR₁₃,COOR₁₃, C₁₋₄ alkoxy, C₁₋₄ alkylthio, hydroxy, phenyl, NR₁₃R₁₄ and 5-6membered heterocyclyl with between 1 and 2 heteroatoms selected from N,O, and S;

[0017] in addition, either R₅ and R₆ or R₆ and R₇ may be taken togetherto be a bivalent moiety, saturated or unsaturated, selected from—(CH₂)₃—, —(CH₂)₄—, and (CH₁₋₂)_(p)N(CH₁₋₂)_(q),

[0018] p is 0-2 and q is 1-3, where the sum (p+q) is at least 2;

[0019] each of R₉ and R₁₀ is independently C₁₋₆ alkyl;

[0020] each of R₁₁, R₁₂, R₁₃ and R₁₄ is independently H or C₁₋₆ alkyl;

[0021] wherein each of the above hydrocarbyl and heterocarbyl moietiesmay be substituted with between 1 and 3 substituents independentlyselected from F, Cl, Br, I, amino, methyl, ethyl, hydroxy, nitro, cyano,and methoxy.

[0022] The invention also features compositions that include one or morecompounds of formula (I) and a pharmaceutical carrier or excipient.

[0023] These compositions and the methods below may further includeadditional pharmaceutically active agents, such as lipid-lowering agentsor blood-pressure lowering agents, or both.

[0024] Another aspect of the invention includes methods of using thedisclosed compounds or compositions in various methods for preventing,treating, or inhibiting the progression of, a disease mediated by PPARalpha. Examples of PPAR alpha-mediated diseases include dyslipidemia andatherosclerosis. Dyslipidemia includes hypertriglyceridemia,hypercholesterolemia, mixed hyperlipidemia, andhypo-HDL-cholesterolemia. For example, dyslipidemia may be one or moreof the following: low HDL (<35 or 40 mg/dl), high triglycerides (>200mg/dl), and high LDL (>150 mg/dl).

[0025] Additional features and advantages of the invention will becomeapparent from the detailed discussion, examples, and claims below.

DETAILED DESCRIPTION

[0026] The invention features the compounds disclosed herein and offormula (I) in the above Summary section, compositions containing them,and methods of using them.

[0027] According to one aspect of the invention, a method of treatmentmay be associated with improvements (e.g., decrease) in the extent,duration, or degree of edema or weight gain normally associated withother existing therapies, such as, for example, PPAR gamma agonists.Therapy that is associated with weight loss, or that is at least weightneutral, is desirable. A decrease in the degree of weight gain or edema,or an actual weight loss, generally improves overall patient health andcomfort.

[0028] According to another aspect of the invention, a method oftreatment may be a treatment for both dyslipidemia and a form of insulinresistance, impaired glucose tolerance, hyperinsulinemia, or Type IIdiabetes (early, intermediate, or late stage), by administering one ormore of the disclosed compounds, optionally with one or more additionalpharmaceutically-active agents. Diabetic patients may also have somedegree of dyslipidemia. Dyslipidemia includes hypertriglyceridemia,hypercholesterolemia, mixed hyperlipidemia, andhypo-HDL-cholesterolemia. For example, dyslipidemia may be one or moreof the following: low HDL (<35 mg/dl for men, or <39 mg/dl for women),high triglycerides (>200 mg/dl), and high LDL (>150 mg/dl). Preferredcompounds of the invention are potent PPAR alpha agonists providingeffects such as elevated serum levels of high density lipoproteins(HDL), improved levels of intermediate density lipoproteins (IDL), andlower serum levels of triglycerides, low density lipoproteins (LDL),atherogenic molecules, and/or free fatty acids (FFA). Such effects areadvantageous for cardiovascular health, to prevent or inhibit theprogression of atherosclerosis or coronary artery disease (CAD). It istherefore desirable to lower levels of triglycerides and LDL, to raiselevels of HDL, and to lower total cholesterol, for example, within theparameters of generally-accepted ranges for these components.

[0029] One object of the invention is a method of treatment for bothdyslipidemia and a PPAR-alpha mediated disease (such as diabetes,insulin resistance, impaired glucose tolerance, or hyperinsulinemia) bythe administration of a single PPAR alpha agonist.

[0030] Another object of the invention is a PPAR-alpha selective agonistthat is useful for (a) treating, preventing, or inhibiting theprogression of both dyslipidemia and a PPAR-alpha mediated disease (suchas diabetes, insulin resistance, impaired glucose tolerance, orhyperinsulinemia); (b) improving (e.g., lowering) serum glucose; (c)improving glucose tolerance; (d) improving serum insulin levels; (e)improving insulin sensitivity; (f) improving (e.g., lowering) serumtriglyceride levels; (g) lowering LDL levels; (h) raising HDL levels;(i) lowering total cholesterol levels; or (j) any combination of theabove.

[0031] The invention is further described below.

[0032] A. Terms

[0033] The following terms are defined below and by their usagethroughout this disclosure.

[0034] “Alkyl” includes optionally substituted straight chain andbranched hydrocarbons with at least one hydrogen removed to form aradical group. Alkyl groups include methyl, ethyl, propyl, isopropyl,butyl, isobutyl, t-butyl, 1-methylpropyl, pentyl, isopentyl, sec-pentyl,hexyl, heptyl, octyl, and so on. Alkyl includes cycloalkyl, such ascyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

[0035] “Alkenyl” includes optionally substituted straight chain andbranched hydrocarbon radicals as above with at least one carbon-carbondouble bond (sp²). Alkenyls include ethenyl (or vinyl), prop-1-enyl,prop-2-enyl (or allyl), isopropenyl (or 1-methylvinyl), but-1-enyl,but-2-enyl, butadienyls, pentenyls, hexa-2,4-dienyl, and so on.Hydrocarbon radicals having a mixture of double bonds and triple bonds,such as 2-penten-4-ynyl, are grouped as alkynyls herein. Alkenylincludes cycloalkenyl. Cis and trans or (E) and (Z) forms are includedwithin the invention.

[0036] “Alkynyl” includes optionally substituted straight chain andbranched hydrocarbon radicals as above with at least one carbon-carbontriple bond (sp). Alkynyls include ethynyl, propynyls, butynyls, andpentynyls. Hydrocarbon radicals having a mixture of double bonds andtriple bonds, such as 2-penten-4-ynyl, are grouped as alkynyls herein.Alkynyl does not include cycloalkynyl.

[0037] “Alkoxy” includes an optionally substituted straight chain orbranched alkyl group with a terminal oxygen linking the alkyl group tothe rest of the molecule. Alkoxy includes methoxy, ethoxy, propoxy,isopropoxy, butoxy, t-butoxy, pentoxy and so on. “Aminoalkyl”,“thioalkyl”, and “sulfonylalkyl” are analogous to alkoxy, replacing theterminal oxygen atom of alkoxy with, respectively, NH (or NR), S, andSO₂. Heteroalkyl includes alkoxy, aminoalkyl, thioalkyl, and so on.

[0038] “Aryl” includes phenyl, naphthyl, biphenylyl, tetrahydronaphthyl,indenyl, and so on, any of which may be optionally substituted. Arylalso includes arylalkyl groups such as benzyl, phenethyl, andphenylpropyl. Aryl includes a ring system containing an optionallysubstituted 6-membered carbocyclic aromatic ring, said system may bebicyclic, bridge, and/or fused. The system may include rings that arearomatic, or partially or completely saturated. Examples of ring systemsinclude indenyl, pentalenyl, 1-4-dihydronaphthyl, indanyl,benzimidazolyl, benzothiophenyl, indolyl, benzofuranyl, isoquinolinyl,and so on.

[0039] “Heterocyclyl” includes optionally substituted aromatic andnonaromatic rings having carbon atoms and at least one heteroatom (O, S,N) or heteroatom moiety (SO₂, CO, CONH, COO) in the ring. Unlessotherwise indicated, a heterocyclic radical may have a valenceconnecting it to the rest of the molecule through a carbon atom, such as3-furyl or 2-imidazolyl, or through a heteroatom, such as N-piperidyl or1-pyrazolyl. Preferably a monocyclic heterocyclyl has between 5 and 7ring atoms, or between 5 and 6 ring atoms; there may be between 1 and 5heteroatoms or heteroatom moieties in the ring, and preferably between 1and 3, or between 1 and 2. A heterocyclyl may be saturated, unsaturated,aromatic (e.g., heteroaryl), nonaromatic, or fused.

[0040] Heterocyclyl also includes fused, e.g., bicyclic, rings, such asthose optionally condensed with an optionally substituted carbocyclic orheterocyclic five-or six-membered aromatic ring. For example,“heteroaryl” includes an optionally substituted six-memberedheteroaromatic ring containing 1, 2 or 3 nitrogen atoms condensed withan optionally substituted five-or six-membered carbocyclic orheterocyclic aromatic ring. Said heterocyclic five-or six-memberedaromatic ring condensed with the said five-or six-membered aromatic ringmay contain 1, 2 or 3 nitrogen atoms where it is a six-membered ring, or1, 2 or 3 heteroatoms selected from oxygen, nitrogen and sulfur where itis a five-membered ring.

[0041] Examples of heterocyclyls include thiazoylyl, furyl, thienyl,pyranyl, isobenzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl,isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl,isoindolyl, indolyl, indazolyl, purinyl, quinolyl, furazanyl,pyrrolidinyl, pyrrolinyl, imdazolidinyl, imidazolinyl, pyrazolidinyl,pyrazolinyl, piperidyl, piperazinyl, indolinyl, and morpholinyl. Forexample, preferred heterocyclyls or heterocyclic radicals includemorpholinyl, piperazinyl, pyrrolidinyl, pyridyl, cyclohexylimino,thienyl, and more preferably, piperidyl or morpholinyl.

[0042] Examples illustrating heteroaryl are thienyl, furanyl, pyrrolyl,imidazolyl, oxazolyl, thiazolyl, benzothienyl, benzofuranyl,benzimidazolyl, benzoxazolyl, benzothiazolyl.

[0043] “Acyl” refers to a carbonyl moiety attached to either a hydrogenatom (i.e., a formyl group) or to an optionally substituted alkyl oralkenyl chain, or heterocyclyl.

[0044] “Halo” or “halogen” includes fluoro, chloro, bromo, and iodo, andpreferably fluoro or chloro as a substituent on an alkyl group, with oneor more halo atoms, such as trifluoromethyl, trifluoromethoxy,trifluoromethylthio, difluoromethoxy, or fluoromethylthio.

[0045] “Alkanediyl” or “alkylene” represents straight or branched chainoptionally substituted bivalent alkane radicals such as, for example,methylene, ethylene, propylene, butylene, pentylene or hexylene.

[0046] “Alkenediyl” represents, analogous to the above, straight orbranched chain optionally substituted bivalent alkene radicals such as,for example, propenylene, butenylene, pentenylene or hexenylene. In suchradicals, the carbon atom linking a nitrogen preferably should not beunsaturated.

[0047] “Aroyl” refers to a carbonyl moiety attached to an optionallysubstituted aryl or heteroaryl group, wherein aryl and heteroaryl havethe definitions provided above. In particular, benzoyl isphenylcarbonyl.

[0048] As defined herein, two radicals, together with the atom(s) towhich they are attached may form an optionally substituted 4-to 7-, 5-to7-, or a 5-to 6-membered ring carbocyclic or heterocyclic ring, whichring may be saturated, unsaturated or aromatic. Said rings may be asdefined above in the Summary of the Invention section. Particularexamples of such rings are as follows in the next section.

[0049] “Pharmaceutically acceptable salts, esters, and amides” includecarboxylate salts, amino acid addition salts, esters, and amides whichare within a reasonable benefit/risk ratio, pharmacologically effectiveand suitable for contact with the tissues of patients without unduetoxicity, irritation, or allergic response. These salts, esters, andamides may be, for example, C₁₋₈ alkyl, C₃₋₈ cycloalkyl, aryl, C₂₋₁₀heteroaryl, or C₂₋₁₀ non-aromatic heterocyclic salts, esters, andamides. Salts, free acids, and esters are more preferable than amides onthe terminal carboxylate/carboxylic acid group on the left of formula(I). Representative salts include hydrobromide, hydrochloride, sulfate,bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate,stearate, laurate, borate, benzoate, lactate, phosphate, tosylate,citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate,glucoheptonate, lactiobionate, and laurylsulfonate. These may includealkali metal and alkali earth cations such as sodium, potassium,calcium, and magnesium, as well as non-toxic ammonium, quaternaryammonium, and amine cations such as tetramethyl ammonium, methylamine,trimethylamine, and ethylamine. See example, S. M. Berge, et al.,“Pharmaceutical Salts,” J. Pharm. Sci., 1977, 66:1-19 which isincorporated herein by reference. Representative pharmaceuticallyacceptable amides of the invention include those derived from ammonia,primary C₁₋₆ alkyl amines and secondary di (C₁₋₆ alkyl) amines.Secondary amines include 5-or 6-membered heterocyclic or heteroaromaticring moieties containing at least one nitrogen atom and optionallybetween 1 and 2 additional heteroatoms. Preferred amides are derivedfrom ammonia, C₁₋₃ alkyl primary amines, and di (C₁₋₂ alkyl)amines.Representative pharmaceutically acceptable esters of the inventioninclude C₁₋₇ alkyl, C₅₋₇cycloalkyl, phenyl, and phenyl(C₁₋₆)alkylesters. Preferred esters include methyl and ethyl esters.

[0050] “Patient” or “subject” includes mammals such as humans andanimals (dogs, cats, horses, rats, rabbits, mice, non-human primates) inneed of observation, experiment, treatment or prevention in connectionwith the relevant disease or condition. Preferably, the patient orsubject is a human.

[0051] “Composition” includes a product comprising the specifiedingredients in the specified amounts as well as any product whichresults from combinations of the specified ingredients in the specifiedamounts.

[0052] “Therapeutically effective amount” or “effective amount” meansthat amount of active compound or pharmaceutical agent that elicits thebiological or medicinal response in a tissue system, animal or humanthat is being sought by a researcher, veterinarian, medical doctor orother clinician, which includes alleviation of the symptoms of thecondition or disorder being treated.

[0053] Concerning the various radicals in this disclosure and in theclaims, three general remarks are made. The first remark concernsvalency. As with all hydrocarbon radicals, whether saturated,unsaturated or aromatic, and whether or not cyclic, straight chain, orbranched, and also similarly with all heterocyclic radicals, eachradical includes substituted radicals of that type and monovalent,bivalent, and multivalent radicals as indicated by the context of theclaims. The context will indicate that the substituent is an alkylene orhydrocarbon radical with at least two hydrogen atoms removed (bivalent)or more hydrogen atoms removed (multivalent). An example of a bivalentradical linking two parts of the molecule is Y in formula (I) whichlinks a phenyl substituted with R₅, R₆, and R₇ to the rest of themolecule.

[0054] Second, radicals or structure fragments as defined herein areunderstood to include substituted radicals or structure fragments.Hydrocarbyls include monovalent radicals containing carbon and hydrogensuch as alkyl, alkenyl, alkynyl, cycloalkyl, and cycloalkenyl (whetheraromatic or unsaturated), as well as corresponding divalent (ormulti-valent) radicals such as alkylene, alkenylene, phenylene, and soon. Heterocarbyls include monovalent and divalent (or multi-valent)radicals containing carbon, optionally hydrogen, and at least oneheteroatom. Examples of monovalent heterocarbyls include acyl, acyloxy,alkoxyacyl, heterocyclyl, heteroaryl, aroyl, benzoyl, dialkylamino,hydroxyalkyl, and so on. Using “alkyl” as an example, “alkyl” should beunderstood to include substituted alkyl having one or moresubstitutions, such as between 1 and 5, 1 and 3, or 2 and 4substituents. The substituents may be the same (dihydroxy, dimethyl),similar (chlorofluoro), or different (chlorobenzyl-oraminomethyl-substituted). Examples of substituted alkyl includehaloalkyl (such as fluoromethyl, chloromethyl, difluoromethyl,perchloromethyl, 2-bromoethyl, trifluoromethyl, and 3-iodocyclopentyl),hydroxyalkyl (such as hydroxymethyl, hydroxyethyl, 2-hydroxypropyl,aminoalkyl (such as aminomethyl, 2-aminoethyl, 3-aminopropyl, and2-aminopropyl), nitroalkyl, alkylalkyl, and so on. A di(C₁₋₆ alkyl)aminogroup includes independently selected alkyl groups, to form, forexample, methylpropylamino and isopropylmethylamino, in additiondialkylamino groups having two of the same alkyl group such as dimethylamino or diethylamino.

[0055] Third, only stable compounds are intended. For example, wherethere is an NR₁₁R₁₂ group, and R can be an alkenyl group, the doublebond is at least one carbon removed from the nitrogen to avoid enamineformation. Similarly, where —(CH₂)_(p)—N—(CH₂)_(q)— can be unsaturated,the appropriate hydrogen atom(s) is (are) included or omitted, as shownin —(CH₂)—N═(CH)—(CH₂)— or —(CH₂)—NH—(CH)═(CH)—.

[0056] Compounds of the invention are further described in the nextsection.

[0057] B. Compounds

[0058] The present invention features compositions containing andmethods of using compounds of formula (I) as described in the Summarysection above. Examples include those compounds wherein: (a) one of R₁and R₂ is methyl or ethyl; (b) wherein each of R₁ and R₂ is methyl; (c)R₁ and R₂ taken together are cyclobutyl or cyclopentyl; (d) R₃ is H; (e)R₄ is H or C₂₋₇ alkyl; (e) P4 is H or C₂₋₅ alkyl; (f) R₄ is ethyl; (g)R₄ is H; (h) n is 1; (i) n is 2; j) Y is NHCH₂; (k) Y is NH; (l) X is S;(m) X is O; (n) at least one of R₅ and R₇ is H; (o) R₆ is C₁₋₄ alkyl,halomethoxy, or halothiomethoxy; (p) R₆ is t-butyl, isopropyl,trifluoromethyl, trifluoromethoxy, trifluorothiomethoxy,difluoromethoxy, or dimethylamino; (q) R₃ is H, R₄ is C₂₋₇ alkyl, and Yis NH; (r) R₄ is C₂₋₅ alkyl; (s) R₆ is cyclopropylmethyl, isopropyl,isobutyl, methylethylamino, or diethylamino; (t) the (S) enantiomer atthe C-2 position on the indane or tetralin; (u) the (R) enantiomer atthe C-2 position on the indane or tetralin; (v) where R₁₅ is C₁₋₇ alkyl,[di(C₁₋₂ alkyl)amino](C₁₋₆ alkylene), (C₁₋₃ alkoxyacyl)(C₁₋₆ alkylene),C₁₋₆ alkoxy, C₃₋₇ alkenyl, or C₃₋₈ alkynyl; (w) R₆ istrifluoromethylthio or trifluoromethoxy; or (x) combinations of theabove.

[0059] Additional preferred compounds include:

2-{6-[1-Ethyl-3-(4-trifluoromethoxy-phenyl)-ureido]-1,4-difluoro-5,6,7,8-tetrahydro-naphthalen-2-ylsulfanyl}-2-methylpropionicacid

[0060]

2-{4-Chloro-6-[1-ethyl-3-(4-trifluoromethoxyphenyl)ureido]-1-fluoro-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid

[0061]

2-{3-Ethyl-6-[1-ethyl-3-(4-trifluoromethoxyphenyl)ureido]-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid

[0062]

3-(1-Carboxy-1-methyl-ethylsulfanyl)-7-[1-ethyl-3-(4-trifluoromethoxyphenyl)ureido]-5,6,7,8-tetrahydronaphthalene-2-carboxylicacid ethyl ester

[0063]

2-{6-[Ethyl-(4-trifluoromethoxyphenoxycarbonyl)-amino]-3-fluoro-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methyl propionic acid2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-methoxy-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid 2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-chloro-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionic acid2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-bromo-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-methyl-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-trifluoromethoxy-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid2-{6-[1-Ethyl-3-(4-hydroxyphenyl)ureido]-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid2-{6-[4-Aminophenyl)-1-ethyl-ureido]-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid

[0064] The most preferred compounds are selected from:

[0065]2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid;

[0066]2-{6-[3-(4-trifluoromethoxyphenyl)ureido]-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid;

[0067]2-{2-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid;

[0068]2-{2-[1-Ethyl-3-(4-trifluoromethylsulfanylphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid;

[0069]2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-fluoro-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid; and

[0070]2-Methyl-2-{2-[1-propyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}propionicacid.

[0071] Related Compounds

[0072] The invention provides the disclosed compounds and closelyrelated, pharmaceutically acceptable forms of the disclosed compounds,such as salts, esters, amides, acids, hydrates or solvated formsthereof; masked or protected forms; and racemic mixtures, orenantiomerically or optically pure forms. Related compounds also includecompounds of the invention that have been modified to be detectable,e.g., isotopically labelled with ¹⁸F for use as a probe in positronemission tomography (PET) or single-photon emission computed tomography(SPECT).

[0073] The invention also includes disclosed compounds having one ormore functional groups (e.g., hydroxyl, amino, or carboxyl) masked by aprotecting group. See, e.g., Greene and Wuts, Protective Groups inOrganic Synthesis, 3^(rd) ed., (1999) John Wiley & Sons, NY. Some ofthese masked or protected compounds are pharmaceutically acceptable;others will be useful as intermediates. Synthetic intermediates andprocesses disclosed herein, and minor modifications thereof, are alsowithin the scope of the invention.

[0074] Hydroxyl Protecting Groups

[0075] Protection for the hydroxyl group includes methyl ethers,substituted methyl ethers, substituted ethyl ethers, substitute benzylethers, and silyl ethers.

[0076] Substituted Methyl Ethers

[0077] Examples of substituted methyl ethers include methyoxymethyl,methylthiomethyl, t-butylthiomethyl, benzyloxymethyl,p-methoxybenzyloxymethyl, (4-methoxyphenoxy)methyl, t-butoxymethyl.

[0078] Substituted Ethyl Ethers

[0079] Examples of substituted ethyl ethers include 1-ethoxyethyl,1-methyl-1-methoxyethyl, 1-methyl-1-benzyloxyethyl,2,2,2-trichloroethyl, t-butyl, allyl, p-chlorophenyl, p-methoxyphenyl,and benzyl.

[0080] Substituted Benzyl Ethers

[0081] Examples of substituted benzyl ethers include p-methoxybenzyl,3,4-dimethoxybenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl,p-phenylbenzyl, diphenylmethyl.

[0082] Esters

[0083] In addition to ethers, a hydroxyl group may be protected as anester. Examples of esters include formate, benzoylformate, acetate,trichloroacetate, trifluoroacetate, methoxyacetate, phenoxyacetate,p-chlorophenoxyacetate, benzoate.

[0084] Sulfonates

[0085] Examples of sulfonates include sulfate,methanesulfonate(mesylate), benzylsulfonate, and tosylate.

[0086] Amino Protecting Groups

[0087] Protection for the amino group includes carbamates, amides, andspecial —NH protective groups.

[0088] Examples of carbamates include methyl and ethyl carbamates,substituted ethyl carbamates, assisted cleavage carbamates, photolyticcleavage carbamates, urea-type derivatives, and miscellaneouscarbamates.

[0089] Carbamates

[0090] Examples of methyl and ethyl carbamates include methyl and ethyl,9-fluorenylmethyl, and 4-methoxyphenacyl.

[0091] Substituted Ethyl

[0092] Examples of substituted ethyl carbamates include2,2,2-trichloroethyl, 2-phenylethyl, t-butyl, vinyl, allyl,1-isopropylallyl, benzyl, p-methoxybenzyl, p-nitrobenzyl, p-bromobenzyl,p-chlorobenzyl, 2,4-dichlorobenzyl and diphenylmethyl.

[0093] Photolytic Cleavage

[0094] Examples of photolytic cleavage include m-nitrophenyl,3,5-dimethoxybenzyl, o-nitrobenzyl, 3,4-dimethoxy-6-nitrobenzyl, andphenyl(o-nitrophenyl)methyl.

[0095] Amides

[0096] Examples of amides include N-formyl, N-acetyl, N-trichloroacetyl,N-trifluoroacetyl, N-phenylacetyl, N-3-phenylpropionyl, N-picolinoyl,N-3-pyridylcarboxamide, N-benzoyl, N-p-phenylbenzoyl, and phthaloyl.

[0097] Protection for the Carbonyl Group

[0098] Cyclic Acetals and Ketals

[0099] Examples of cyclic acetals and ketals include 1,3-dioxanes and5-methylene-1,3-dioxane.

[0100] Protection for the Carboxyl Group

[0101] Esters

[0102] Substituted Methyl Esters

[0103] Examples of substituted methyl esters include 9-fluorenylmethyl,methoxymethyl, methylthiomethyl, methoxyethoxymethyl,2-(trimethylsilyl)ethoxymethyl, benzyloxymethyl, phenacyl,p-bromophenacyl, α-methylphenacyl, and p-methoxyphenacyl. Examples ofesters also include straight chain or branched alkyl esters such astert-butyl, ethyl, propyl, isopropyl, and butyl.

[0104] Substituted Benzyl Esters

[0105] Examples of substituted benzyl esters include triphenylmethyl,diphenylmethyl, 9-anthrylmethyl, 2,4,6-trimethylbenzyl, p-bromobenzyl,o-nitrobenzyl, p-nitrobenzyl, p-methoxybenzyl, 2,6-dimethoxybenzyl,piperonyl, 4-picolyl and p-P-benzyl.

[0106] Silyl Esters

[0107] Examples of silyl esters include trimethylsilyl, triethylsilyl,t-butyldimethylsilyl, i-propyldimethylsilyl, phenyldimethylsilyl anddi-t-butylmethylsilyl.

[0108] C. Synthetic Methods

[0109] The invention provides methods of making the disclosed compoundsaccording to traditional organic synthetic methods as well as matrix orcombinatorial synthetic methods. Schemes 1 through 10 describe suggestedsynthetic routes. Using these Schemes, the guidelines below, and theexamples, a person of skill in the art may develop analogous or similarmethods for a given compound that are within the invention.

[0110] One skilled in the art will recognize that synthesis of thecompounds of the present invention may be effected by purchasing anintermediate or protected intermediate compounds described in any of theschemes disclosed herein. One skilled in the art will further recognizethat during any of the processes for preparation of the compounds in thepresent invention, it may be necessary and/or desirable to protectsensitive or reactive groups on any of the molecules concerned. This maybe achieved by means of conventional protecting groups, such as thosedescribed in “Protective Groups in Organic Synthesis”, John Wiley &Sons, 1991. These protecting groups may be removed at a convenient stageusing methods known from the art.

[0111] Examples of the described synthetic routes include SyntheticExamples 1 through 57. Compounds analogous to the target compounds ofthese examples can be, and in many cases, have been, made according tosimilar routes. The disclosed compounds are useful in basic research andas pharmaceutical agents as described in the next section.

[0112] General Guidance

[0113] A preferred synthesis of Formula 14, when X is S (and R₃ is H) isdemonstrated in Schemes 1-5.

[0114] Abbreviations or acronyms used herein include:

[0115] AcOH (glacial acetic acid); DCC (1,3-dicyclohexylcarbodiimide);

[0116] DCE (1,2-dichloroethane); DIC (2-dimethylaminoisopropyl chloridehydrochloride); DIEA (diisopropylethylamine); DMF (dimethylformamide);EDC (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide); EtOAc (ethylacetate); mCPBA (3-chloroperoxybenzoic acid); NMI (1-methylimidazole);TEA (triethylamine); TFA (trifluoroacetic acid); THF (tetrahydrofuran);TMEDA (N,N,N′,N′-tetramethyl-ethylenediamine).

[0117] In accordance with Scheme 1, the tetralins can be made byconversion of compound 1 to compound 2. For example, amethoxy-2-tetralone, such as 6-methoxy-2-tetralone, can be treated witha reagent such as ammonium acetate or ammonia, or hydroxylamine. Thecorresponding imine can be reduced with an appropriate reducing agent,such as sodium borohydride, sodium cyanoborohydride, or sodiumtriacetoxyborohydride and the resulting oxime can be reducedcatalytically using palladium or platinum in a polar protic solvent,such as methanol, ethanol or ethyl acetate, to obtain a racemic compound2. Preparation of the hydrochloride salt may be easily accomplished byone skilled in the art.

[0118] In accordance with Scheme 2, the indanes can be prepared byconversion of a compound 3 to a compound 5. For example, when a methoxyindanone, such as 5-methoxy-1-indanone, is treated with an acylatingagent, such as butyl nitrite or isoamyl nitrite in the presence of acatalytic amount of acid, such as hydrochloric acid or hydrobromic acidin a polar solvent, such as methanol or ether, a keto-oxime 4 isobtained. Reduction of a compound 4 can be achieved by using theappropriate reducing agent(s), such as lithium aluminum hydride orhydrogen and a catalyst, such as palladium or platinum, in anappropriate solvent, such as acetic acid-sulfuric acid, THF, or methanolat an appropriate temperature. The choice of salt formation methods maybe easily determined by one skilled in the art.

[0119] In accordance with Scheme 3, a compound 2 or 5 can be convertedto a compound 12. For example, when a racemic amine hydrochloride istreated with a base, such as sodium hydride or lithium hydride in apolar aprotic solvent, such as DMF or THF and consequently reacted withan anhydride, such as phthalic anhydride at elevated temperatures, acyclic imide 6 can be furnished. Cleavage of methyl aryl ethers ofFormula 6 to a compound of the Formula 7 can be accomplished using aLewis acid such as boron tribromide, boron trichloride, aluminumchloride or trimethylsilyliodide in nonpolar, aprotic solvents such astoluene, dichloromethane, or dichloroethane with or without cooling.Acylation of phenols of Formula 7 to a compound of Formula 8 can beachieved using thiocarbamoyl chlorides, such asdimethylaminothiocarbamoyl chloride or diethylthiocarbamoyl chloride anda non-reactive, tertiary amine, such as triethylamine,1,8-diazabicyclo[5.4.0]undec-7-ene, or 1,4-diazabicyclo[2.2.2.]octane inan aprotic solvent such as dichloromethane, DMF, or THF with or withoutcooling. Compounds of Formula 8 can be rearranged thermally to compoundsof Formula 9 at temperatures between 180° C. to 350° C., either neat asa melt or using high-boiling solvents such as DOWTHERM® A (a mixture ofbiphenyl and biphenyl ether sold by, for example, Fluka Chemical Corp.,Milwaukee, Wis. USA), N,N-dimethylaniline, diphenyl ether or decalin.Compounds of Formula 10 can be prepared from compounds of Formula 9 bytreating with a suitable nucleophile, such as hydrazine, disodiumsulfide or methylamine in appropriate polar solvent such as ethanol orTHF at elevated temperatures. Conversion of Formula 10 to compounds ofFormula 11 can be achieved using an appropriate reagent, such aspotassium hydroxide in an alchoholic solvent, such as ethanol ormethanol, or lithium aluminum hydride in THF or ether, followed byalkylation using an appropriately substituted alkyl halide, such astert-butyl 2-bromoisobutyrate, ethyl bromoacetate, or ethyl2-bromobutyrate and a reducing agent, such as lithium borohydride orsodium borohydride. Compounds of Formula 11 can be substituted toprovide compounds of Formula 12 using a carboxylic acid or an acidchloride and an appropriate reducing agent such as borane-THF orborane-dimethylsulfide, using aprotic solvents such as THF,dichloromethane, or hexanes. Alternatively, substitution can beaccomplished using an aldehyde and a reducing agent, such as sodiumcyanoborohydride or sodium triacetoxyborohydride, in appropriate aproticsolvents, such as THF, dichloromethane or dichloroethane.

[0120] In accordance to Scheme 4, compounds of Formula 13 can beprepared from compounds of Formula 12 by acylating a secondary aminewith an aryl acetic acid, using thionyl chloride or oxalyl chloride neator in toluene or dichloromethane with or without catalytic DMF.Alternatively, the coupling can be achieved using standard peptideconditions, such as EDC, DCC, or DIC in dichloromethane. When Y=NH or O,an aryl isocyanate or aryl chloroformate, respectively, in a non-polaraprotic solvent, such as THF, dichloromethane or hexanes can be used toprovide compounds of Formula 13. The choice of deprotection methods maybe easily determined by one skilled in the art to provide compounds ofFormula 14.

[0121] Likewise, compounds of Formula 16 can be prepared from compoundsof Formula 11 by acylating the primary amine as delineated in Scheme 5to afford compounds of Formula 15. The choice of deprotection methodsmay be easily determined by one skilled in the art to provide compoundsof Formula 16.

[0122] A compound of Formula 18 can be prepared from a compound ofFormula 10 as demonstrated in Scheme 6. For example, compound of Formula10 can be treated with ethyl formate or ammonium formate either neat orin the presence of a suitable solvent, such as dichloromethane ordichloroethane with or without heating to provide a compound of Formula17. Compounds of Formula 17 can be converted to compounds of Formula 18by using an appropriate reagent, such as lithium aluminum hydride in asuitable solvent, such as THF or ether followed by alkylation using anappropriately substituted alkyl halide, such as tert-butyl2-bromoisobutyrate, ethyl bromoacetate, or ethyl 2-bromobutyrate and areducing agent, such as lithium borohydride or sodium borohydride.

[0123] A preferred synthesis of Formula 21, when X is O (and R₃ is H) isdemonstrated in Scheme 7. For example, when compounds of Formula 2 or 5are acylated with a carboxylic acid or an acid chloride as describedpreviously, compounds of Formula 19 are prepared. Cleavage of methylaryl ethers of Formula 19 to a compound of the Formula 20 can beaccomplished using a Lewis acid such as boron tribromide, borontrichloride, aluminum chloride or trimethylsilyliodide in nonpolar,aprotic solvents such as toluene, dichloromethane, or dichloroethanewith or without cooling. Compounds of Formula 20 can be converted tocompounds of Formula 21 by treating with an appropriate base, such aspotassium carbonate, cesium carbonate or potassium hydroxide and anappropriately substituted alkyl halide, such as tert-butyl2-bromoisobutyrate, ethyl bromoacetate, or ethyl 2-bromobutyrate in asuitable solvent, such as DMF or methanol.

[0124] Compounds of Formula 24 can be prepared from compounds of Formula22 as demonstrated in Scheme 8. For example, compound of Formula 22 canbe treated with an appropriate base, such as butyl lithium or sec-butyllithium in an appropriate solvent, such as ether or THF, with or withoutTMEDA and cooling, and the appropriate electrophile, such as alkylhalides, aldehydes, or disulfides to provide compounds of Formula 23.Compounds of Formula 23 can be converted to compounds of Formula 24 in amanner analogous to that described in Scheme 3 for the transformation ofcompound 8 to compound 9.

[0125] An alternative synthesis toward compounds of Formula 32 isoutlined in Scheme 9. For example, when 4-methylthiophenyl acetic acid,Formula 26, is treated with oxalyl chloride or thionyl chloride in thepresence of methanol, a compound of Formula 27 is afforded. Treatment ofcompounds of Formula 27 with a Lewis acid, such as aluminum chloride, ina chlorinated solvent such as chloroform or dichloroethane, in thepresence of an alkene, such as ethylene, provides tetralones of Formula28. Using the procedure outlined in Scheme 1, the tetralins of Formula29 can be prepared. Compounds of Formula 29 can be substituted toprovide compounds of Formula 30 using a carboxylic acid under couplingconditions outlined previously or an acid chloride with a tertiaryamine, such as diisopropylethylamine or triethylamine in a suitablesolvent, such as dichloromethane or dichloroethane. A compound ofFormula 30 can converted to a compound of Formula 31 using with anoxidizing agent, such as mCPBA or hydrogen peroxide in a suitablesolvent, such as methylene chloride, followed by subsequent treatment ofcompounds of Formula 30 with trifluoroacetic anhydride with or without asolvent, such as chloroform, followed by treatment with a tertiaryamine, such as triethylamine or diisopropylethylamine in a suitablesolvent, such as methanol affords compounds of Formula 31.Alternatively, deprotection of the thio ether in compounds of Formula 30can be achieved using a base, such as tert-butyl sodium sulfide, sodium,sodium methyl thiol in a suitable solvent, such as DMF,N-methyl-2-pyrrolidone or ammonia to provide compounds of Formula 31.Using chemistry analogous to that described in Scheme 3 for thetransformation of compound 10 to compound 11, compounds of Formula 31can be readily converted to compounds of Formula 32.

[0126] In accordance to Scheme 10, compounds of Formula 22 can bereadily converted to compounds of Formula 32a, where R₃═OCH₃. Forexample, compounds of Formula 22 can be treated with an appropriatebase, such as butyl lithium or sec-butyl lithium in an appropriatesolvent, such as ether or THF, with or without TMEDA and cooling, andthe appropriate disulfide, such as dimethyl disulfide or dibenzyldisulfide provide compounds of Formula 33. Removal of the dimethylaminothiocarbamate from compounds of Formula 33 is achieved using potassiumor sodium hydroxide in an appropriate solvent, such as water, methanol,or ethanol with or without heating, to afford compounds of Formula 34.Compounds of Formula 34 can be methylated to provide compounds ofFormula 19a by using methyl iodide, dimethylsulfate, or diazomethane inan appropriate solvent, such as DMF, methanol, or dichloromethane, withor without base, such as cesium carbonate or potassium carbonate. Usingchemistry analogous to that described in Scheme 9 for the transformationof compounds of Formula 30 to Compounds of Formula 32, Compounds ofFormula 32a can be readily synthesized from Compounds of Formula 19a.

[0127]2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenylureido]-5,6,7,8-tetrahydronaphthal-2-ylsulfanyl}-2-methyl-propionicacid.

Compound 1.0 EXAMPLE 1

[0128] A. 6-Methoxy-1,2,3,4-tetrahydronaphthalen-2-ylaminehydrochloride.

[0129] Scheme 1. To a solution of 6-methoxy-2-tetralone (10.0 g; 56.7mmol) dissolved in MeOH (400 mL) is added ammonium acetate (65 g; 0.84mol) and the reaction was stirred for 30 min. at RT. To the reaction isthen added sodium cyanoborohydride (17.8 g; 0.28 mol) and the reactionwas refluxed for 1-2 h. The reaction is cooled, the solvent removedunder reduced pressure, the residue diluted with EtOAc and 1 N NaOHadded to quench the reaction. The aqueous phase is separated and theorganic phase washed with H₂O, brine, dried over Na₂SO₄, filtered, andthe solvent removed under reduced pressure to afford a crude residuewhich was purified by flash chromatography (SiO₂) eluting withCH₂Cl₂/MeOH:NH₄OH (10%) to provide 5.0 g (50%) of6-methoxy-1,2,3,4-tetrahydro-naphthalen-2-ylamine as a dark oil. To asolution of titled compound in ether (100 mL) cooled to 0° C. is bubbledHCl (g) until the solution is saturated. The suspension is stirred foran additional 30 min at RT and the solvent evaporated under reducedpressure. The remaining solid is triturated with ether, filtered, washedwith ether and dried under reduced pressure to provide 4.9 g of6-methoxy-1,2,3,4-tetrahydronaphthalen-2-ylamine hydrochloride as awhite solid.

[0130] LC/MS: C₁₁H₁₅NO: m/z 178 (M+1)

[0131] B.2-(6-Methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)isoindole-1,3-dione.

[0132] Scheme 3. To a stirred suspension of 60% NaH (6 g; 0.182 mmol) inDMF (400 mL) is added 6-methoxy-1,2,3,4-tetrahydronaphthalen-2-ylamine(30 g; 0.140 mol), portionwise at 0° C. The reaction mixture is warmedto RT and stirred for an additional 1 h. Phthalic anhydride (20.7 g;0.139 mol) is added in 1-portion at RT, upon which the reaction mixtureis stirred for an additional 1 h followed by 18 h at 120° C. Thereaction was allowed to cool to RT, diluted with H₂O and extractedseveral times with EtOAc. The combined organic extracts are washed withwater, brine, dried over Na₂SO₄, and the solvent removed under reducedpressure. The crude solid was triturated with MeOH, filtered, and driedunder vacuo to afford 29.1 g (67%) of2-(6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)isoindole-1,3-dione as anoff-white solid.

[0133]¹H NMR (300 MHz, CDCl₃): δ 7.83-7.86 (m, 2H), 7.70-7.73 (m, 2H),6.96-6.99 (d, 1H), 6.67-6.72 (m, 2H), 4.50-4.59 (m, 1H), 3.78 (s, 3H),3.52-3.61 (m, 1H), 2.95-2.98 (m, 2H), 2.81-2.88 (m, 1H), 2.65-2.76 (m,1H), 1.97-2.01 (m, 1H)

[0134] LC/MS: C₁₉H₁₇NO₃: m/z 308 (M+1)

[0135] C.2-(6-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)isoindole-1,3,dione.

[0136] Scheme 3. To2-(6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)isoindole-1,3-dione (29g; 94.3 mmol) dissolved in anhydrous CH₂Cl₂ (500 mL), cooled to −60° C.,is added a 1.0 M solution of boron tribromide-CH₂Cl₂ (471 mL), dropwiseto maintain reaction temperature between −50 to −60° C. Upon completionof the addition, the reaction mixture is allowed to warm to RT andstirred for an additional 4 h. The reaction is cooled to 0° C., quenchedwith saturated NaHCO₃ (400 mL) and stirred for an additional 0.5 h atRT. The precipitate is filtered, washed thoroughly with H₂O, suspendedin ether, filtered and dried under vacuo to afford 25.4 g (92%) of2-(6-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)isoindole-1,3-dione as anoff-white solid.

[0137]¹H NMR (300 MHz, DMSO-d₆): δ 9.11 (bs, 1H), 7.82-7.89 (m, 4H),6.84-6.87 (d, 1H), 6.52-6.56 (m, 2H), 4.294.37 (m, 1H), 3.45 (bs, 1H),3.25-3.34 (m, 1H), 2.73-2.84 (m, 3H), 2.37-2.47 (m, 1H), 1.94-1.98 (m,1H)

[0138] LC/MS: C₁₈H₁₅NO₃: m/z 294 (M+1)

[0139] D. Dimethyl-thiocarbamicacid-O-[6-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-5,6,7,8-tetrahydro-naphthalen-2-yl]ester.

[0140] Scheme 3. To2-(6-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)isoindole-1,3-dione (25.4g; 86.5 mmol) dissolved in anhydrous DMF (200 mL) is added1,4-diazabicyclo[2.2.2]octane (48.5 g; 4.32 mol) followed bydimethylaminothio-carbamoyl chloride (53.4 g; 4.32 mol) and the solutionwas stirred at RT for 4 h. The reaction is poured over ice-water (1 L)and stirred for 18 h. The precipitate was filtered, washed with H₂O anddried under vacuo. The crude solid was purified by flash chromatography(SiO₂) eluting with a hexanes-EtOAc gradient to afford 30 g (91%) ofdimethylthiocarbamic acid—O-[6-(1,3-dioxo-1,3,-dihydroisoindol-2-yl)-5,6,7,8-tetrahydronaphthalen-2-yl]ester as a white solid.

[0141]¹H NMR (300 MHz, CDCl₃): δ 7.83-7.86 (m, 2H), 7.70-7.73 (m, 2H),7.07-7.10 (d, 1H), 6.83-6.86 (m, 2H), 4.54-4.65 (m, 1H), 3.60-3.69 (m,1H), 3.46 (s, 3H), 3.34 (s, 3H), 2.88-3.09 (m, 3H), 2.64-2.78 (m, 1H),1.97-2.01 (m, 1H)

[0142] LC/MS: C₂₁H₂₀N₂O₃S: m/z 381 (M+1)

[0143] E. Dimethylthiocarbamic acidS-[6-(1,3-dioxo-1,3-dihydroisoindol-2-yl)-5,6,7,8-tetrahydronaphthalen-2-yl]ester.

[0144] Scheme 3. To a 50 mL round-bottom flask equipped with a refluxcondenser and stir bar, preheated to 330° C. in a sand-bath, is addeddimethyl-thiocarbamic acidO-[6-(1,3-dioxo-1,3-dihydroisoindol-2-yl)-5,6,7,8-tetrahydronaphthalen-2-yl]ester (5.32 g; 13.9 mmol) in 1-portion. The melt is stirred for 7-8 min.at 330° C., then rapidly cooled to RT with a N₂ stream. The cruderesidue is purified by flash chromatography (SiO₂) eluting with ahexanes-EtOAc gradient to provide 3.1 g (58%) of dimethylthiocarbamicacidS-[6-(1,3-dioxo-1,3-dihydroisoindol-2-yl)-5,6,7,8-tetrahydronaphthalen-2-yl]ester as a white solid.

[0145]¹H NMR (300 MHz, CDCl₃): δ 7.82-7.86 (m, 2H), 7.72-7.75 (m, 2H),7.23-7.26 (m, 2H), 7.07-7.10 (d, 1H), 4.52-4.63 (m, 1H), 3.61-3.70 (m,1H), 2.89-3.09 (m, 9H), 2.61-2.75 (m, 1H), 1.97-2.04 (m, 1H)

[0146] LC/MS: C₂₁H₂₀N₂O₃S: m/z 381 (M+1)

[0147] F. Dimethylthiocarbamic acidS-[6-amino-5,6,7,8-tetrahydronaphthalen-2-yl) ester.

[0148] Scheme 3. A 3-neck flask, equipped with a reflux condensor andmechanical stirrer, is charged with EtOH (115 mL) anddimethylthiocarbamic acidS-[6-(1,3-dioxo-1,3-dihydroisoindol-2-yl)-5,6,7,8-tetrahydronaphthalen-2-yl]ester (8.7 g; 23.5 mmol). Hydrazine (6.6 mL; 2.11 mol) is added in1-portion at RT and the reaction was refluxed with mechanical stirringfor 40 min. The reaction is cooled to RT and the gelatinous, white solidis filtered and washed thoroughly with ether. The ether washes arecombined, evaporated under reduced pressure and the crude residue wasfurther triturated with ether, filtered and the ether evaporated underreduced pressure to afford 6.1 g (100%) of dimethylthiocarbamic acidS-[6-amino-5,6,7,8-tetrahydronaphthalen-2-yl) ester as a yellow oil.

[0149] LC/MS: C₁₃H₁₈N₂OS: m/z 251 (M+1)

[0150] G.2-(6-Amino-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl)-2-methylpropionicacid tert-butyl ester.

[0151] Scheme 3. To dimethylthiocarbamic acidS-[6-amino-5,6,7,8-tetrahydronaphthalen-2-yl) ester (6.1 g; 24.4 mmol),dissolved in MeOH (25 mL) is added a solution of KOH (4.1 g; 73.2 mmol)in MeOH (25 mL) at RT. The solution is stirred at reflux for 5 h andcooled to RT. tert-Butyl 2-bromoisobutyrate (16.3 g; 73.2 mmol) is addedto the solution and stirred for 16 h at RT. NaBH₄ (9.2 g; 2.44 mol) isadded and the reaction is stirred for an additional 48 h at RT. Thereaction is quenched with H₂O, the solvent evaporated under reducedpressure, and the crude residue partitioned between H₂O and CH₂Cl₂. Theaqueous phase is extracted with CH₂Cl₂ and the combined organic extractswere dried over Na₂SO₄, filtered and evaporated under reduced pressureto afford 4.7 g (60%) of2-(6-amino-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl)-2-methylpropionicacid tert-butyl ester as a brown oil. LC/MS: C₁₈₁H₂₇NO₂S: m/z 266 (M+1)

[0152] H.2-(6-Acetylamino-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl)-2-methylpropionic acid tert-butyl ester.

[0153] Scheme 3. To2-(6-amino-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl)-2-methylpropionicacid tert-butyl ester (4.7 g; 14.6 mmol), dissolved in CH₂Cl₂ (25 mL),is added DIEA (3.3 mL; 18.9 mmol) and the reaction mixture is cooled to0° C. Acetyl chloride (1.25 mL; 17.5 mmol) is added dropwise at a rateto maintain the temperature between 0-5° C. The reaction was allowed towarm to RT and stirred for 16 h. The reaction was diluted with CH₂Cl₂,washed with H₂O, dried over Na₂SO₄ and evaporated under reducedpressure. The crude oil was purified by flash chromatography (SiO₂)eluting with a hexanes-EtOAc gradient to afford 1.7 g (32%) of2-(6-acetylamino-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl)-2-methylpropionicacid tert-butyl ester as a tan solid.

[0154]¹H NMR (300 MHz, CDCl₃): δ 7.23-7.26 (m, 2H), 6.99-7.01 (d, 1H),5.46-5.48 (m, 1H), 4.25-4.29 (m, 1H), 3.08-3.15 (dd, 1H), 2.82-2.88 (m,2H), 2.58-2.66 (m, 1H), 2.01-2.04 (m, 1H), 1.98 (s, 3H), 1.70-1.82 (m,1H), 1.43 (s, 15H)

[0155] LC/MS: C₂₀H₂₉NO₃S: m/z 308 (M+1)

[0156] I.2-(6-Ethylamino-5.6,7,8-tetrahydronaphthalen-2-ylsulfanyl)-2-methylpropionicacid tert-butyl ester.

[0157] Scheme 3. To a solution of2-(6-acetylamino-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl)-2-methylpoprionicacid tert-butyl ester (1.79; 4.64 mmol) in THF (42 mL) is added asolution of 1.0 M borane-THF (42 mL), dropwise at RT. The reaction wasallowed to stir for 18 h at RT, carefully quenched with MeOH and thesolvent was evaporated under reduced pressure. The residual oil wasfurther azeotroped with MeOH (3×) to afford 1.9 g (100%) of a mixture of2-(6-ethylamino-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl)-2-methylpropionicacid tert-butyl ester and it's borane complex as an oil.

[0158] LC/MS: C₂₀H₃₁NO₂S.BH₃: m/z 308 ((M+BH₃)+1)

[0159] J.2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid tert butyl ester.

[0160] Scheme 4. To a mixture of2-(6-ethylamino-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl)-2-methylpropionicacid tert-butyl ester and borane complex (1.9 g; 5.2 mmol) dissolved inCH₂Cl₂ (15 mL) is added 4-trifluoromethoxyphenyl isocyanate (1.6 g; 7.8mmol) and the reaction was stirred at RT for 18 h. The solvent wasremoved under reduced pressure and the crude residue was purified byflash chromatography (SiO₂) eluting with a hexanes-EtOAc gradient toprovide 1.66 g (58%) of2-{6-[1-ethyl-3-(4-trifluoromethoxyphenyl)ureido]-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid tert butyl ester as a white foam.

[0161] LC/MS: C₂₈H₃₅F₃N₂O₄S: m/z 497 ((M−C₄H₈)+1)

[0162] K.2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid.

[0163] Scheme 4. To2-{6-[1-ethyl-3-(4-trifluoromethoxyphenyl)ureido]-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid tert butyl ester (1.66 g; 3.0 mmol) dissolved in CH₂Cl₂ (15 mL) isadded TFA (15 mL) and the reaction was stirred at RT for 1.5 h. Thesolvent was removed under reduced pressure and the residue was purifiedby flash chromatography (SiO₂) eluting with a hexanes-EtOAc gradient toafford 0.643 g (43%) of2-{6-[1-ethyl-3-(4-trifluoromethoxyphenyl)ureido]-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid as a white solid.

[0164]¹H NMR (300 MHz, CD₃OD): δ 7.45-7.48 (m, 2H), 7.06-7.24 (m, 5H),4.44 (m, 1H), 3.43-3.45 (m, 2H), 2.96-3.02 (m, 4H), 2.00-2.05 (m, 2H),1.41-1.46 (s, 6H), 1.21-1.29 (m, 3H)

[0165] LC/MS: C₂₄H₂₇F₃N₂O₄S: m/z 497 (M+1)

[0166]2-{2-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid.

[0167] Compound 2.0

EXAMPLE 2

[0168] A. 5-Methoxyindan-1,2-dione-2-oxime.

[0169] Scheme 2. To a solution of 5-methoxyindan-1-one (75.8 g; 0.467mol) in MeOH (1.4 L) at 45° C. is added butyl nitrite (81 mL; 0.693 mol)dropwise over 45 min. Concentrated HCl (45 mL) is then added to the hotsolution over 20 min and the reaction was allowed to stir at 45° C. foran additional 1.5-2 h. The reaction suspension is cooled, theprecipitate filtered, washed several times with cold MeOH, and driedunder vacuo to afford 55.8 g (62%) of 5-methoxyindan-1,2-dione-2-oximeas a beige solid.

[0170]¹H NMR (300 MHz, CD₃OD): δ 7.80-7.83 (m, 1H), 6.95 (bs, 2H), 3.92(s, 3H), 3.78 (s, 2H), 3.47 (bs, 1H)

[0171] LC/MS: C₁₀H₉NO₃: m/z 192 (M+1)

[0172] B. 5-Methoxyindan-2-ylamine hydrochloride.

[0173] Scheme 2. To 5-methoxyindan-1,2-dione-2-oxime (55.7 g; 0.291mol), suspended in glacial acetic acid (0.99 L) is added concentratedH₂SO₄ (67 mL) followed by 10% PdC (27 g) and the reaction is mixed on aParr apparatus under H₂ at 60 psi for 18 h. The reaction is purged withN₂, filtered through a pad of celite and washed with AcOH. The solventis removed under reduced pressure to ⅕ volume and the remaining solventis diluted with H₂O (500 mL), cooled to 0° C., and neutralized to pH 10with 50% aqueous NaOH. The aqueous phase is extracted extensively withCHCl₃ several times and the extracts are combined, washed with H₂O,brine, dried over Na₂SO₄, filtered and evaporated under reduced pressureto provide 77.3 g (66%) of a crude oil. The oil was subjected to flashchromatography (SiO₂) eluting with 40:2.2:0.2 CHCl₃:MeOH:NH₄OH toprovide 43.8 g (37%) of a dark oil. The oil is dissolved in ether (1 L),cooled to 0° C., and the solution is saturated with HCl (g). The solventwas removed under reduced pressure and the solid triturated with ether,filtered, and washed with ether to provide 43.8 g (30%) of5-methoxyindan-2-ylamine hydrochloride as a white solid.

[0174]¹H NMR (300 MHz, CD₃OD): δ 7.08-7.11 (d, 1H), 6.77 (s, 1H),6.69-6.72 (d, 1H), 3.78-3.85 (m, 1H), 3.77 (s, 3H), 3.08-3.19 (m, 2H),2.57-2.68 (m, 2H), 1.51 (s, 2H)

[0175] LC/MS: C₁₀H₉NO₃: m/z 192 (M+1)

[0176] M.P. =240-241° C.

[0177] C. 2-(5-Methoxyindan-2-yl)isoindole-1.3-dione.

[0178] Scheme 3. To a suspension of 60% NaH (8 g; 0.240 mol) in DMF (250mL), cooled to 0° C., is added 5-methoxyindan-2-ylamine hydrochloride(40.0 g; 0.2 mol) and the suspension stirred for 1 h at RT. Phthalicanhydride (30 g; 0.2 mol) is added in 1-portion and the suspensionstirred for an additional 1-1.5 h at RT followed by stirring at 120° C.for 96 h. The reaction is cooled and diluted with EtOAc. The organicphase is washed with H₂O, the resultant precipitate filtered, washedwith EtOAc, MeOH and dried under vacuo to afford 25.2 g (43%) of2-(5-methoxyindan-2-yl)isoindole-1,3-dione as a white solid. The organicphase is washed with H₂O, evaporated under reduced pressure and thesolid is triturated with MeOH, filtered, and dried to afford anadditional 19.7 (33%) g of 2-(5-methoxyindan-2-yl)isoindole-1,3-dione asa white solid.

[0179]¹H NMR (300 MHz, CD₃OD): δ 7.83-7.87 (m, 2H), 7.68-7.74 (m, 2H),7.10-7.13 (d, 1H), 6.73-6.78 (m, 2H), 5.08-5.21 (m, 1H), 3.79 (s, 3H),3.48-3.65 (m, 2H), 3.07-3.18 (m, 2H)

[0180] LC/MS: C₁₈H₁₅NO₃: m/z 294 (M+1)

[0181] D. 2-(5-Hydroxyindan-2-yl)isoindole-1,3-dione.

[0182] Scheme 3. To 2-(5-methoxyindan-2-yl)isoindole-1,3-dione (19.7 g;67 mmol) dissolved in anhydrous CH₂Cl₂ (350 mL) and cooled to −60° C.,is added a 1.0 M solution of boron tribromide-CH₂Cl₂ (340 mL), dropwiseat a rate to maintain the internal temperature between −50 and −60° C.The reaction mixture is allowed to warm to RT and stirred for anadditional 5 h. The reaction is cooled to 0° C., quenched with saturatedNaHCO₃ (500 mL) and stirred for an additional 0.5 h at RT. Theprecipitate is filtered, washed with H₂O, suspended in ether, filteredand dried under vacuo to afford 14.8 g (79%) of2-(5-hydroxyindan-2-yl)isoindole-1,3-dione as a beige solid.

[0183]¹H NMR (300 MHz, DMSO-d₆): δ 9.16 (s, 1H), 7.82-7.91 (m, 4H),6.98-7.01 (d, 1H), 6.56-6.62 (m, 2H), 4.91-5.03 (m, 1H), 3.27-3.43 (m,3H), 2.99-3.10 (m, 2H)

[0184] LC/MS: C₁₇H₁₃NO₃: m/z 280 (M+1)

[0185] F. Dimethylthiocarbamic acidO-[2-(1,3-dioxo-1,3-dihydroisoindol-2-yl)indan-5-yl]ester.

[0186] Scheme 3. To 2-(5-hydroxyindan-2-yl)isoindole-1,3-dione (31 g;0.11 mol) dissolved in anhydrous DMF (400 mL) is added1,4-diazabicyclo[2.2.2]-octane (62 g; 0.55 mol) followed bydimethylaminothiocarbamoyl chloride (68 g; 0.55 mol) and the solutionwas stirred at RT for 16 h. The reaction is poured over ice-water (1 L)and stirred for 18 h. The precipitate was filtered, washed with H₂O anddried under vacuo to afford 41.6 g (100%) of dimethylthiocarbamic acidO-[2-(1,3-dioxo-1,3-dihydroisoindol-2-yl)indan-5-yl] ester as a beigesolid.

[0187]¹H NMR (300 MHz, CDCl₃): δ 7.82-7.87 (m, 2H), 7.69-7.75 (m, 2H),7.17-7.24 (d, 1H), 6.87-6.93 (m, 2H), 5.13-5.25 (m, 1H), 3.53-3.68 (m,2H), 3.46 (s, 3H), 3.34 (s, 3H), 3.09-3.23 (m, 2H)

[0188] G. Dimethylthiocarbamic acidS-[2-(1,3-dioxo-1,3-dihydroisoindol-2-yl)indan-5-yl]ester.

[0189] Scheme 3. To a 50 mL round-bottom flask, equipped with a refluxcondenser and stir bar, preheated to 330° C. in a sand-bath is addeddimethylthiocarbamic acidO-[2-(1,3-dioxo-1,3-dihydroisoindol-2-yl)indan-5-yl] ester (6.30 g; 18.7mmol) in 1-portion. The melt is stirred for 12 min. at 338° C., rapidlycooled to RT with a N₂ stream and the crude residue purified by flashchromatography (SiO₂) eluting with a hexanes-EtOAc gradient to afford3.88 g (61%) of dimethylthiocarbamic acidS-[2-(1,3-dioxo-1,3-dihydroisoindol-2-yl)indan-5-yl] ester as anoff-white solid.

[0190]¹H NMR (300 MHz, CDCl₃): δ 7.81-7.87 (m, 2H), 7.69-7.74 (m, 2H),7.22-7.36 (m, 3H), 5.10-5.22 (m, 1H), 3.59-3.67 (m, 2H), 3.06-3.23 (m,9H)

[0191] LC/MS: C₂₀H₁₈N₂O₃S: m/z 367 (M+1)

[0192] H. Dimethylthiocarbamic acid S-(2-aminoindan-5-yl) ester.

[0193] Scheme 3. A 3-neck flask, equipped with a reflux condensor andmechanical stirrer, is charged with EtOH (98 mL) anddimethylthiocarbamic acidS-[2-(1,3-dioxo-1,3-dihydroisoindol-2-yl)indan-5-yl] ester (6.9 g; 20.6mmol). Hydrazine (5.8 mL; 186 mmol) is added in 1-portion at RT and thereaction was refluxed with mechanical stirring for 30 min. The reactionis cooled to RT and the gelatinous, white solid is filtered and washedwith ether several times. The ether washes are combined, evaporatedunder reduced pressure and the crude residue was further triturated withether, filtered and the ether evaporated under reduced pressure toafford 4.6 g (95%) of dimethylthiocarbamic acid S-[2-aminoindan-5-yl)ester as a brown oil.

[0194]¹H NMR (300 MHz, CDCl₃): δ 7.15-7.33 (m, 3H), 3.80-3.88 (m, 1H),3.05-3.22 (m, 8H), 2.64-2.72 (m, 1H), 2.17 (bs, 2H)

[0195] LC/MS: C₁₂H₁₆N₂OS: m/z 237 (M+1)

[0196] I. 2-(2-Aminoindan-5-ylsulfanyl)-2-methylpropionic acidtert-butyl ester.

[0197] Scheme 3. To dimethylthiocarbamic acid S-(2-aminoindan-5-yl)ester (4.9 g; 20.9 mmol), dissolved in MeOH (60 mL) is added a solutionof KOH (11.8 g; 0.210 mol) in MeOH (110 mL) at RT. The solution isstirred at reflux for 5 h and cooled to RT. tert-Butyl2-bromoisobutyrate (7.0 g; 31.3 mmol) is added to the solution andstirred for 18 h at RT. The solvent is evaporated under reduced pressureand the crude residue partitioned between H₂O and EtOAc. The aqueousphase is extracted with EtOAc and the combined organic extracts werewashed with H₂O, brine, dried over Na₂SO₄, filtered and evaporated underreduced pressure to afford 4.9 g (76%) of2-(2-aminoindan-5-ylsulfanyl)-2-methylpropionic acid tert-butyl ester asa brown oil.

[0198] LC/MS: C₁₇H₂₅NO₂S: m/z 308 (M+1)

[0199] J. 2-(2-Acetylaminoindan-5-ylsulfanyl)-2-methylpropionic acidtert-butyl ester.

[0200] Scheme 3. To 2-(2-aminoindan-5-ylsulfanyl)-2-methylpropionic acidtert-butyl ester (14.6 g; 47.4 mmol), dissolved in CH₂Cl₂ (100 mL), isadded TEA (8.6 mL; 61.7 mmol) and the reaction mixture is cooled to 0°C. Acetyl chloride (4.1 mL; 57.6 mmol) is added dropwise at a rate tomaintain the temperature between 100-5° C. The reaction was allowed towarm to RT, stirred for 16 h, diluted with CH₂Cl₂, washed with H₂O,dried over Na₂SO₄ and evaporated under reduced pressure. The crude oilwas purified by flash chromatography (SiO₂) eluting with a hexanes-EtOAcgradient to afford 11.7 g (71%) of2-(2-acetylaminoindan-5-ylsulfanyl)-2-methylpropionic acid tert-butylester as a beige solid.

[0201]¹H NMR (300 MHz, CDCl₃): δ 7.31-7.35 (m, 2H), 7.15-7.18 (d, 1H),5.73 (m, 1H), 4.68-4.78 (m, 1H), 3.25-3.39 (dd, 2H), 2.74-2.80 (d, 2H),1.94 (s, 3H), 1.43 (s, 15H)

[0202] LC/MS: C₁₉H₂₇NO₃S: m/z 294 (M+1)

[0203] K. 2-(2-Ethylaminoindan-5-ylsulfanyl)-2-methylpropionic acidtert-butyl ester.

[0204] Scheme 3. To a solution of2-(2-acetylaminoindan-5-ylsulfanyl)-2-methylpropionic acid tert-butylester (11.7 g; 33.5 mmol) in THF (280 mL) is added a solution of 1.0 Mborane-THF (226 mL), dropwise at RT. The reaction was allowed to stirfor 5 h at RT, cooled to 0° C., quenched with MeOH (100 mL) andevaporated under reduced pressure. The residual oil was furtherazeotroped with MeOH (3×) to afford 11 g (100%) of a mixture of2-(2-ethylaminoindan-5-ylsulfanyl)-2-methylpropionic acid tert-butylester and its borane complex as an oil.

[0205] LC/MS: C₁₉H₂₉NO₂SBH₃: m/z 336 ((M+BH₃)+1)

[0206] L.2-[2-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl]-2-methylpropionicacid tert butyl ester.

[0207] Scheme 4. To a mixture of2-(2-ethylaminoindan-5-ylsulfanyl)-2-methylpropionic acid tert-butylester and borane complex (11.0 g; 33 mmol), dissolved in CH₂Cl₂ (100mL), is added 4-trifluoromethoxyphenyl isocyanate (10.2 g; 50.2 mmol)and the reaction was allowed to stir at RT for 18 h. The solvent wasremoved under reduced pressure and the crude residue was purified byflash chromatography (SiO₂) eluting with a hexanes-EtOAc gradient toafford 11.2 g (62%) of2-{2-[1-ethyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid tert butyl ester as a white foam.

[0208]¹H NMR (300 MHz, CDCl₃): δ 7.30-7.36 (m, 4H), 7.10-7.19 (m, 3H),6.31 (s, 1H), 4.97-5.08 (m, 1H), 3.22-3.39 (m, 4H), 3.01-3.09 (dd, 2H),1.42-1.44 (m, 15H), 1.23-1.28 (t, 3H)

[0209] LC/MS: C₂₇H₃₃F₃N₂O₄S: m/z 483 ((M-C₄H₈)+1)

[0210] M.2-{2-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid.

[0211] Scheme 4. To2-{2-[1-ethyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid tert butyl ester (4.8 g; 8.91 mmol) dissolved in CH₂Cl₂ (15 mL) isadded TFA (15 mL) and the reaction was stirred at RT for 2 h. Thesolvent was removed under reduced pressure and the residue was purifiedby flash chromatography (SiO₂) eluting with a hexanes-EtOAc gradient toafford 3.13 g (73%) of2-{2-[1-ethyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid as a white solid.

[0212]¹H NMR (300 MHz, CDCl₃): δ 7.29-7.35 (m, 4H), 7.15-7.17 (d, 1H),7.08-7.11 (d, 2H), 6.45 (s, 1H), 4.94-5.04 (m, 1H), 3.18-3.36 (m, 4H),2.98-3.07 (m, 2H), 1.48 (s, 6H), 1.19-1.28 (t, 3H)

[0213] LC/MS: C₂₃H₂₅F₃N₂O₄S: m/z 483 (M+1)

[0214] M.P. =73-77° C.

[0215] The following 14 compounds were prepared following Schemes 3 and4 and Steps J, K, L and M of Route 2, substituting reagents andadjusting reaction conditions as needed:

[0216](S)-2-{2-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid.

[0217] Intermediate L (11 g) of Route 2 was resolved by chiralchromatography (Chiralpak AD column; isocratic gradient withhexane/methanol/ethanol: 92/4/4) to provide (S)-intermediate L (4.8 g).Using Step M of Route 2, Compound 2.1 (3.1 g) was prepared.

[0218] LC/MS: C₂₃H₂₅F₃N₂O₄S: m/z 483 (M+1)

[0219]2-{2-[1-Ethyl-3-(4-trifluoromethylsulfanylphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid.

[0220] Compound 2.2 (0.33 g; 57% for 2 steps; white solid) was preparedfollowing Route 2 by replacing 4-trifluoromethoxyphenyl isocyanate with4-trifluorothiomethoxy isocyanate.

[0221]¹H NMR (CD₃OD); δ 1.16-1.20 (t, 3H), 1.38 (s, 6H), 3.09-3.23 (m,4H), 3.37-3.44 (q, 2H), 4.95-5.06 (m, 1H), 7.14-7.17 (m, 1H), 7.32-7.35(m, 1H), 7.40 (s, 1H), 7.55 (s, 4H)

[0222] LC/MS: C₂₃H₂₅F₃N₂O₃S₂: m/z 499 (M+1)

[0223]2-Methyl-2-{2-[1-pentyl-3-(4-trifluoromethylsulfanylphenyl)ureido]indan-5-ylsulfanyl}propionicacid

[0224] Compound 2.3 (0.22 g; 32% for 2 steps; white solid) was preparedfollowing Route 2 and Compound 2.2 by replacing acetyl chloride withvaleryl chloride.

[0225]¹H NMR (CD₃OD); δ 0.844-0.890 (t, 3H), 1.20-1.31 (m, 4H), 1.39 (s,6H), 1.45-1.58 (m, 2H), 3.07-3.22 (m, 6H), 4.89-4.99 (m, 1H), 7.15-7.18(m, 1H), 7.33-7.35 (m, 2H), 7.33-7.35 (m, 1H), 7.40 (s, 1H), 7.50-7.57(m, 4H)

[0226] LC/MS: C₂₆H₃₁F₃N₂O₃S₂: m/z 541 (M+1)

[0227] 2-{2-[1-Ethyl-3-(4isopropylphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionic acid

[0228] Compound 2.4 (0.18 g; 34% for 2 steps; white solid) was preparedfollowing Route 2 by replacing 4-trifluoromethoxyphenyl isocyanate with4-isopropylphenyl isocyanate.

[0229]¹H NMR (CD₃OD); δ 1.16-1.23 (m, 9H), 1.38 (s, 6H), 2.82-2.87 (m,1H), 3.10-3.21 (m, 4H), 3.37-3.39 (m, 2H), 4.99-5.04 (m, 1H), 7.14-7.17(m, 3H), 7.23-7.26 (m, 2H), 7.32-7.50 (m, 2H), 7.40 (s, 1H)

[0230] LC/MS: C₂₅H₃₂N₂O₃S: m/z 441 (M+1)

[0231]2-{2-[3-(4-Dimethylaminophenyl)-1-ethylureido]indan-5-ylsulfanyl}-2-methylpropionicacid

[0232] Compound 2.5 (0.34 g; 66% for 2 steps; white solid) was preparedfollowing Route 2 by replacing 4-trifluoromethoxyphenyl isocyanate with4-dimethylaminophenyl isocyanate.

[0233]¹H NMR (CD₃OD); δ 1.15-1.20 (t, 3H), 1.42 (s, 6H), 2.88 (s, 1H),3.05-3.69 (m, 4H), 3.31-3.69 (m, 2H), 4.94-5.06 (m, 1H), 6.78-6.81 (m,2H), 7.16-7.21 (m, 3H), 7.29-7.41 (m, 2H)

[0234] LC/MS: C₂₄H₃₁N₃O₃S: m/z 442 (M+1)

[0235]2-Methyl-2-{2-[1-pentyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid

[0236] Compound 2.6 (0.29 g; 77% for 2 steps; white solid) was preparedfollowing Route 2 by replacing acetyl chloride with valeryl chloride.

[0237]¹H NMR (CD₃OD); δ 0.847-0.893 (t, 3H), 1.20-1.29 (m, 4H), 1.39 (s,6H), 1.58-1.60 (m, 2H), 3.04-3.29 (m, 6H), 4.89-4.99 (m, 1H), 7.14-7.17(m, 3H), 7.32-7.34 (m, 1H), 7.40-7.45 (m, 3H)

[0238] LC/MS: C₂₆H₃₁F₃N₂O₄S: m/z 525 (M+1)

[0239]2-{2-[3-(4-Dimethylaminophenyl)-1-pentylureido]indan-5-ylsulfanyl}-2-methylpropionicacid

[0240] Compound 2.7 (0.25 g; 36% for 2 steps; white solid) was preparedfollowing Route 2 and compound 2.5 by replacing acetyl chloride withvaleryl chloride.

[0241]¹H NMR (CD₃OD); δ 0.869-0.915 (t, 3H), 1.17-1.31 (m, 4H), 1.44 (s,6H), 1.57-1.65 (m, 2H), 2.91 (s, 6H), 3.12-3.29 (m, 6H), 4.94-5.02 (m,1H), 6.80-6.83 (d, 2H), 7.17-7.23 (m, 3H), 7.32-7.38 (m, 2H)

[0242] LC/MS: C₂₇H₃₇N₃O₃S: m/z 484 (M+1)

[0243]2-{2-[3-(4-Isopropylphenyl)-1-(3-pentyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid

[0244] Compound 2.8 (5 mg; 14% for 2 steps; white solid) was preparedfollowing Route 2 and compound 2.4 by replacing acetyl chloride withvaleryl chloride.

[0245] LC/MS: C₂₈H₃₈N₂O₃S: m/z 483 (M+1)

[0246]2-{2-[3-(4-tert-butylphenyl)-1-(3-pentyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid

[0247] Compound 2.9 (4 mg; 9% for 2 steps; white solid) was preparedfollowing Route 2 and compound 2.3 by replacing 4-trifluorothiophenylisocyanate with 4-tert-butylphenyl isocyanate.

[0248] LC/MS: C₂₉H₄₀N₂O₃S: m/z 497 (M+1)

[0249]2-[2-(3-(Biphenyl-4-yl-1-pentylureido)indan-5-ylsulfanyl]-2-methylpropionicacid

[0250] Compound 2.10 (3 mg; 7% for 2 steps; white solid) was preparedfollowing Route 2 and compound 2.3 by replacing 4-trifluorothiophenylisocyanate with 4-biphenylyl isocyanate.

[0251] LC/MS: C₃₁H₃₆N₂O₃S: m/z 517 (M+1)

[0252] 2-{2-[3-(4-Isopropylphenyl)-1-(3-hexyl)ureido]indan-5-ylsulfanyl}-2-methylpropionic acid

[0253] Compound 2.11 (13 mg; 44% for 2 steps; oil) was preparedfollowing Route 2 and Compound 2.4 by replacing valeryl chloride withcaproyl chloride.

[0254] LC/MS: C₂₉H₄₀N₂O₃S: m/z 497 (M+1)

[0255]2-Methyl-2-{2-[1-hexyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}propionicacid

[0256] Compound 2.12 (18 mg; 54% for 2 steps; white solid) was preparedfollowing Route 2 by replacing valeryl chloride with caproyl chloride.

[0257] LC/MS: C₂₇H₃₃F₃N₂O₄S: m/z 539 (M+1)

[0258]2-Methyl-2-{2-[1-hexyl-3-(4-trifluoromethylsulfanylphenyl)ureido]indan-5-ylsulfanyl}propionicacid

[0259] Compound 2.13 (14 mg; 36% for 2 steps; white solid) was preparedfollowing Route 2 and Compound 2.2 by replacing valery chloride withcaproyl chloride.

[0260] LC/MS: C₂₇H₃₃F₃N₂O₃S₂: m/z 555 (M+1)

[0261]2-Methyl-2-{2-[1-propyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}propionicacid

[0262] Compound 2.14 (1.2 mg; 3% for 2 steps; oil) was preparedfollowing Route 2 by replacing acetyl chloride with propionyl chloride.

[0263] LC/MS: C₂₄H₂₇F₃N₂O₄S: m/z 497 (M+1)

[0264] 2-Methyl-2-{2-[1-butyl-3-(4-trifluoromethylsulfanylphenyl)ureido]indan-5-ylsulfanyl}propionic acid

[0265] Compound 2.15 (11 mg; 32% for 2 steps; oil) was preparedfollowing Route 2 and Compound 2.2 by replacing acetyl chloride withbutyryl chloride.

[0266] LC/MS: C₂₅H₂₉F₃N₂O₃S₂: m/z 527 (M+1)

[0267]2-Methyl-2-{2-[3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}propionicacid

[0268] Compound 2.16 (11 mg; 49% for 2 steps; oil) was preparedfollowing Route 2 by acylating with 4-trifluoromethoxyphenyl isocyanate.

[0269] LC/MS: C₂₁H₂₁F₃N₂O₄S: m/z 455 (M+1)

[0270] Route 3

[0271]2-Methy-2-{2-[1-pent-4-enyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}propionicacid

[0272] To 2-(2-aminoindan-5-ylsulfanyl)-2-methylpropionic acidtert-butyl ester (0.220 g; 0.72 mmol), dissolved in DCE (4 mL), is addedpent-4-enal (0.060 mg; 0.72 mmol) followed by sodiumtriacetoxyborohydride (0.21 g; 1.0 mmol) and the reaction mixturestirred for 18 h at RT. The reaction mixture was diluted with CH₂Cl₂,washed with H₂O, brine, dried over Na₂SO₄, filtered and the solventevaporated under reduced pressure to afford2-methyl-2-(2-pent-4-enylaminoindan-5-ylsulfanyl)propionic acidtert-butyl ester as a crude oil.

[0273] Compound 3.0 (0.149 mg; 40% for 3 steps; white solid) wasprepared following Route 2 and steps L and M by acylating with4-trifluoromethoxyphenyl isocyanate.

[0274] LC/MS: C₂₆H₂₉F₃N₂O₄S: m/z 522 (M+1)

[0275] The following 2 compounds were prepared following Schemes 3 and4, Route 3, Steps L and M of Route 2, substituting reagents andadjusting reaction conditions as needed:

[0276]2-Methyl-2-{2-[1-(3-methylbutyl)-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid

[0277] Compound 3.1 (13 mg; 29% for 3 steps; white solid) was preparedfollowing Route 3 substituting pent-4-enal with isobutyraldehyde andacylating with 4-trifluoromethoxyphenyl isocyanate.

[0278] LC/MS: C₂₆H₃₁F₃N₂O₄S: m/z 525 (M+1)

[0279] 2-{2-[3-(4-Isopropylphenyl)-1-(3-methylbutyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid

[0280] Compound 3.2 (11 mg; 27% for 3 steps; white solid) was preparedfollowing Route 3 and compound 3.1 by replacing 4-trifluoromethoxyphenylisocyanate with 4-isopropylphenyl isocyanate.

[0281]¹H NMR (CD₃OD); δ 0.877-0.895 (dd, 6H), 1.19-1.22 (dd, 6H),1.42-1.53 (m, 9H), 2.80-2.89 (m, 1H), 2.99-3.08 (m, 2H), 3.17-3.48 (m,4H), 4.98-5.03 (m, 1H), 6.26 (s, 1H), 7.10-7.22 (m, 5H), 7.32-7.35 (m,2H)

[0282] LC/MS: C₂₈H₃₈N₂O₃S: m/z 483 (M+1)

[0283] The following 3 compounds were prepared following Schemes 1 and 3and Steps J and K of Route 1, substituting reagents and adjustingreaction conditions as needed:

[0284]2-{6-[1-Butyl-3-(4-trifluoromethoxyphenyl)ureido]-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid

[0285] Compound 1.1 (41 mg; 68% for 2 steps; white solid) was preparedfollowing Route 1 by replacing acetyl chloride with butyryl chloride.

[0286] LC/MS: C₂₆H₃₁F₃N₂O₄S: m/z 525 (M+1)

[0287]2-{6-[1-Butyl-3-(4-trifluoromethylsulfanylphenyl)ureido]-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid

[0288] Compound 1.2 (23 mg; 34% for 2 steps; white solid) was preparedfollowing Route 1 and compound 1.1 by replacing acetyl chloride withbutyryl chloride and 4-trifluoromethoxyphenyl isocyanate with4-trifluorothiophenyl isocyanate.

[0289] LC/MS: C₂₆H₃₁F₃N₂O₃S₂: m/z 541 (M+1)

[0290]2-{6-[1-Hexyl-3-(4-trifluoromethoxyphenyl)ureido]-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionic acid

[0291] Compound 1.3 (36 mg; 57% for 2 steps; white solid) was preparedfollowing Route 1 by replacing acetyl chloride with caproyl chloride.

[0292] LC/MS: C₂₈H₃₅F₃N₂O₄S: m/z 553 (M+1)

[0293] The following 2 compounds were prepared following Schemes 3 and 4and Steps L and M of Route 2, substituting reagents and adjustingreaction conditions as needed:

[0294]2-{2-[3-(3-Bromo-4-trifluoromethoxyphenyl)-1-ethylureido]indan-5-ylsulfanyl}-2-methylpropionicacid

[0295] Compound 2.17 (0.018 g; 19% for 3 steps; white solid) wasprepared following Route 2 by replacing 4-trifluoromethoxy phenylisocyanate with 3-bromo-4-trifluoromethoxyphenyl isocyanate. To3-bromo-4-trifluoromethoxy aniline (0.214 g; 0.836 mmol) in THF (1 mL)is added di-tert-butyl dicarbonate (0.255 g; 1.17 mmol) followed by4-dimethylaminopyridine (0.102 g; 0.835 mmol). After the effervesenceceases (30 min.), a solution of2-(2-ethylaminoindan-5-ylsulfanyl)-2-methylpropionic acid tert-butylester (0.058 g; 0.167 mmol) in THF (1 mL) is added and the reactionmixture stirred for 18 h at RT.

[0296] Using Steps K and L of Route 2, the titled compound was prepared.

[0297] LC/MS: C₂₃H₂₄BrF₃N₂O₄S: m/z 563 (M+1)

[0298]2-{2-[1-Ethyl-3-(3-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid

[0299] Compound 2.18 (13 mg; 12% for 3 steps; white solid) was preparedfollowing Example 2.0 by replacing 4-trifluoromethoxyphenyl isocyanatewith 3-trifluoromethoxyphenyl isocyanate. To a solution ofcarbonyldiimidazole (0.454 g; 2.8 mmol) in THF (2 mL), heated to 50° C.,is added 3-trifluoromethoxyaniline (0.522 g; 2.94 mmol), dropwise. After15 min. the reaction is cooled and added to a solution of2-(2-ethylaminoindan-5-ylsulfanyl)-2-methylpropionic acid tert-butylester (0.077 g; 0.22 mmol) in THF (1 mL).

[0300] LC/MS: C₂₃H₂₅F₃N₂O₄S: m/z 483 (M+1)

[0301]2-{2-[3-(4-Dimethylaminophenyl)-1-methylureido]indan-5-ylsulfanyl}-2-methylpropionicacid

[0302] A. Dimethylthiocarbamic acid S-(2-formylamino-indan-5-yl)ester.

[0303] Scheme 6. To dimethylthiocarbamic acid-S-[2-aminoindan-5-yl)ester (2.0 g; 8.46 mmol) in CHCl₃ (10 mL) is added ethyl formate (50 mL)and the reaction heated at 55° C. for 24 h. The reaction is cooled, thesolvent removed under reduced pressure, and the crude oil purified byflash chromatography (SiO₂) eluting with an ethyl acetate-methanolgradient to afford 0.77 g (35%) of dimethylthiocarbamicacid-S-(2-formylaminoindan-5-yl)ester as a white solid.

[0304] LC/MS: C₁₃H₁₆N₂O₂: m/z 264 (M+1)

[0305] B. 2-Methyl-2-(2-methylaminoindan-5-ylsulfanyl)-propionic acidtert-butyl ester.

[0306] Scheme 6. To dimethylthiocarbamic acidS-(2-formylaminoindan-5-yl)ester (0.772 g; 2.9 mmol) in THF (9 mL) underN₂ is added a solution of 1.0 M lithium aluminum hydride (9 mL) at 0° C.The reaction is warmed to RT then stirred at reflux for 24 h. Thereaction is cooled to 0° C., quenched with H₂O, and the solvent removedunder reduced pressure. The residue is dissolved in MeOH (4 mL), towhich is added Cs₂CO₃ (0.304 g; 0.93 mmol), tert-butyl2-bromoisobutyrate (0.311 mL; 1.39 mmol), and NaBH₄ (2.0 g; 52.8 mmol).The reaction mixture is stirred for 18 h, the removed under reducedpressure and the residue partitioned between EtOAc and H₂O. The layersare separated, the aqueous phase extracted with EtOAc, the organicextracts combined, washed with brine, dried over Na₂SO₄, filtered andevaporated under reduced pressure. The crude residue is purified byflash chromatography (SiO₂) eluting with a CH₂Cl₂-MeOH gradient toafford 0.186 g (20%) of2-methyl-2-(2-methylaminoindan-5-ylsulfanyl)propionic acid tert-butylester as an oil.

[0307] LC/MS: C₁₈H₂₇NO₂S: m/z 321 (M+1)

[0308] Compound 2.19 (44 mg; 65% for 2 steps; white solid) was preparedfollowing Route 2 and Steps L and M by replacing4-trifluoromethoxyphenyl isocyanate with 4-dimethylaminophenylisocyanate.

[0309] LC/MS: C₂₃H₂₉N₃O₃S: m/z 428 (M+1)

[0310]2-{2-[1-(3-Cyclopentylpropyl)-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid

[0311] Compound 2.20 (39 mg; 49% for 2 steps; white solid) was preparedfollowing Route 2 by replacing acetyl chloride with3-cyclopentylpropionyl chloride.

[0312] LC/MS: C₂₉H₃₅F₃N₂O₄S: m/z 565 (M+1)

[0313]2-[2-(3-indan-5-yl-1-pentylureido)indan-5-ylsulfanyl}-2-methylpropionicacid

[0314] Compound 2.21 (9.3 mg; 24% for 2 steps; white solid) was preparedfollowing Route 2 and Compound 2.3 by replacing acetyl chloride withvaleryl chloride and 4-trifluoromethoxyphenyl isocyanate with indanylisocyanate.

[0315] LC/MS: C₂₈H₃₆N₂O₃S: m/z 481 (M+1)

[0316]2-Methyl-2-{2-[3-(4-methyl-3-nitrophenyl)-1-pentylureido]indan-5-ylsulfanyl}propionic acid

[0317] Compound 2.22 (5.0 mg; 12% for 2 steps; white solid) was preparedfollowing Route 2 and compound 2.3 by replacing 4-trifluoromethoxyphenylisocyanate with 4-methyl-3-nitrophenyl isocyanate.

[0318] LC/MS: C₂₆H₃₃N₃O₅S: m/z 500 (M+1)

[0319] 2-Methyl-2-{2-[1-naphthalen-1ylmethyl-3-(4-trilfuoromethoxyphenyl)-ureido]indan-5-ylsulfanyl}-propionicacid

[0320] Compound 3.4 (2.9 mg; 4% for 2 steps; white solid) was preparedfollowing Route 3 by replacing pent-4-enal with 1-naphthaldehyde.

[0321] LC/MS: C₃₂H₂₉F₃N₂O₄S: m/z 595 (M+1)

[0322]2-{2-[3-(4-Methoxyphenyl)-1-propylureido]indan-5-ylsulfanyl}-2-methylpropionicacid

[0323] Compound 2.23 (21 mg; 64% for 2 steps; white solid) was preparedfollowing Route 2 and Compound 2.14 by replacing4-trifluoromethoxyphenyl isocyanate with 4-methoxyphenyl isocyanate.

[0324] LC/MS: C₂₄H₂₇F₃N₂O₄S: m/z 443 (M+1)

[0325]2-{2-[3-(3,5-Dimethylphenyl)-1-propylureido]indan-5-ylsulfanyl}-2-methylpropionicacid

[0326] Compound 2.24 (19 mg; 57% for 2 steps; white solid) was preparedfollowing Route 2 and Compound 2.14 by replacing4-trifluoromethoxyphenyl isocyanate with 3,5-dimethylphenyl isocyanate.

[0327] LC/MS: C₂₅H₃₂N₂O₃S: m/z 441 (M+1)

[0328]2-{2-[1-(2-Methoxyethyl)-3-(4-trifluoromethylsulfanylphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid

[0329] Compound 2.25 (7.0 mg; 16% for 2 steps; oil) was preparedfollowing Route 2 and Compound 2.2 by replacing acetyl chloride withmethoxyacetyl chloride.

[0330] LC/MS: C₂₄H₂₇F₃N₂O₄S₂: m/z 529 (M+1)

[0331]2-Methyl-2-{2-[1-propyl-3-(4-trifluoromethylphenyl)ureido]indan-5-ylsulfanyl}-propionicacid

[0332] Compound 2.26 (20 mg; 56% for 2 steps; white solid) was preparedfollowing Route 2 and Compound 2.14 by replacing4-trifluoromethoxyphenyl isocyanate with 4-trifluoromethylphenylisocyanate.

[0333] LC/MS: C₂₄H₂₇F₃N₂O₃S₂: m/z 481 (M+1)

[0334]2-Methyl-2-{2-[1-(4,4,4-trifluorobutyl)-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}propionicacid

[0335] Compound 2.27 (10 mg; 26% for 2 steps; oil) was preparedfollowing Route 2 and Compound 2.0 by replacing acetyl chloride withtrifluoromethylbutyryl chloride.

[0336] LC/MS: C₂₅H₂₆F₆N₂O₄S: m/z 564 (M+1)2-{2-[1-(3-Cyclopentylpropyl)-3-phenylureido]indan-5-ylsulfanyl}-2-methylpropionicacid

[0337] Compound 2.28 (38 mg; 56% for 2 steps; oil) was preparedfollowing Route 2 and Compound 2.0 by replacing acetyl chloride withcyclopentylpropionyl chloride and 4-trifluoromethoxyphenyl isocyanatewith phenyl isocyanate.

[0338] LC/MS: C₂₈H₃₆N₂O₃S: m/z 481 (M+1)

[0339]6-[1-[5-(1-Carboxy-1-methylethylsulfanyl)indan-2-yl]-3-(4-isopropylphenyl)-ureido]hexanoicacid methyl ester

[0340] Compound 2.29 (12 mg; 38% for 2 steps; white solid) was preparedfollowing Route 2 and Compound 2.4 by replacing acetyl chloride with5-chlorocarbonyl-pentanoic acid methyl ester.

[0341] LC/MS: C₃₀H₄₀N₂O₅S: m/z 541 (M+1)

[0342]2-Methyl-2-[2-(3-naphthalen-2-yl-1-pentylureido)indan-5-ylsulfanyl]propionicacid

[0343] Compound 2.30 (15 mg; 39% for 2 steps; white solid) was preparedfollowing Route 2 and Compound 2.3 by replacing4-trifluorothiomethoxyphenyl isocyanate with 2-naphthyl isocyanate.

[0344] LC/MS: C₂₉H₃₄N₂O₃S: m/z 491 (M+1)

[0345]2-{2-[1-Cyclohexylmethyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl]-2-methylpropionicacid

[0346] Compound 2.31 (15 mg; 25% for 2 steps; white solid) was preparedfollowing Route 2 and Compound 2.0 by replacing acetyl chloride withcyclohexylacetyl chloride.

[0347] LC/MS: C₂₈H₃₃F₃N₂O₄S: m/z 551 (M+1)

[0348]2-{2-[1-isobutyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid

[0349] Compound 3.5 (10 mg; 12% for 2 steps; oil) was prepared followingRoute 3 and Compound 3.0 by replacing pent-5-enal with2-methylpropionaldehyde.

[0350] LC/MS: C₂₅H₂₉F₃N₂O₄S: m/z 511 (M+1)

[0351]2-{2-[3-(3,4-Dichlorophenyl)-1-heptylureido]indan-5-ylsulfanyl}-2-methylpropionicacid

[0352] Compound 2.32 (6.7 mg; 12% for 2 steps; oil) was preparedfollowing Route 2 and Compound 2.0 by replacing acetyl chloride withheptanoyl chloride and 4-trifluoromethoxyphenyl isocyanate with3,4-dichlorophenyl isocyanate.

[0353] LC/MS: C₂₇H₃₄Cl₂N₂O₃S: m/z 538 (M+1)

[0354]2-{2-[1-(2-Dimethylaminoethyl)-3-(4-trifluoromethylsulfanylphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid

[0355] Compound 2.33 (1.9 mg; 4% for 2 steps; oil) was preparedfollowing Route 2 and Compound 2.2 by replacing acetyl chloride withdimethylamino acetyl chloride and 4-trifluoromethoxyphenyl isocyanatewith 4-trifluoromethylthiophenyl isocyanate. LC/MS: C₂₅H₃₀F₃N₃O₃S₂: m/z542 (M+1)

[0356]2-{2-[3-(3-Chlorophenyl)-1-heptylureido]indan-5-ylsulfanyl}-2-methylpropionicacid

[0357] Compound 2.34 (7.4 mg; 14% for 2 steps; white solid) was preparedfollowing Route 2 and Compound 2.32 and 4-trifluoromethoxyphenylisocyanate with 3-chlorophenyl isocyanate.

[0358] LC/MS: C₂₇H₃₅ClN₂O₃S: m/z 542 (M+1)

[0359]1-{2-[1-Heptyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}-cyclobutanecarboxylicacid

[0360] Compound 2.35 (1.0 mg; 1.3% for 2 steps; white solid) wasprepared following Route 2 and Compound 2.32 by replacing tert-butyl2-bromoisobutyrate with ethyl 1-bromocyclobutanecarboxylate.

[0361] LC/MS: C₂₉H₃₅F₃N₂O₄S: m/z 565 (M+1)

[0362]2-Methyl-2-{7-[1-propyl-3-(4-trifluoromethoxyphenyl)ureido}-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}propionicacid

[0363] Compound 1.4 (53 mg; 25% for 2 steps; oil) was prepared followingRoute 1 and Compound 1.0 by replacing acetyl chloride with propionylchloride.

[0364] LC/MS: C₂₅H₂₉F₃N₂O₄S: m/z 511 (M+1)

[0365] The following two compounds can be prepared following Schemes 10and 4, Steps I, J and K of Route 1, substituting reagents and adjustingreaction conditions as needed:

[0366]2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-methoxy-5,6,7,8-tetrahydronaphthale-2-ylsulfanyl}-2-methylpropionicacid.

[0367] Compound 1.5 (9.8 mg; oil) can be prepared following Route 1,steps 1, J, and K and Schemes 4 and 10.

[0368]¹H NMR (300 MHz, CD₃OD): δ 7.45-7.48 (d, 2H), 7.15-7.18 (m, 3H),6.71 (s, 1H), 4.43-4.79 (m, 1H), 3.75 (s, 3H), 3.43-3.45 (m, 2H),2.88-3.08 (m, 4H), 1.99-2.03 (m, 2H), 1.38 (s, 6H), 1.25-1.52 (t, 3H)

[0369] LC/MS: C₂₅H₂₉F₃N₂O₅S: m/z 527 (M+1)

[0370]2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-5,6,7,8-tetrahydronaphthalen-2-yloxy}-2-methylpropionicacid. Compound 4.0 (Example 48)

[0371] A. N-(6-Methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)acetamide.

[0372] Scheme 7. To a stirred suspension of6-methoxy-1,2,3,4-tetrahydronaphthalen-2-ylamine (2.54 g; 14.3 mmol) inCH₂Cl₂ (20 mL) is added DIEA (3.4 mL) and the reaction mixture wascooled to 0° C. Acetyl chloride (1.22 mL; 17.1 mmol) is added dropwiseat 0° C. and the reaction is allowed to warm to RT and stirred for 18 h.The reaction mixture was diluted with CH₂Cl₂, washed with H₂O, driedover Na₂SO₄, filtered and the solvent removed under reduced pressure toprovide a crude solid. Purification by flash chromatography (SiO₂)eluting with hexanes-EtOAc affords 1.57 g (50%) ofN-(6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)acetamide as a whitesolid.

[0373] LC/MS: C₁₃H₁₇NO₂: m/z 220 (M+1)

[0374] B. N-(6-Hydroxy-1.2,3,4-tetrahydronaphthalen-2-yl)acetamide.

[0375] Scheme 7. To a suspension ofN-(6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)acetamide (1.57 g; 7.2mmol) in CH₂Cl₂ (70 mL), cooled to −60° C., is added a solution of borontribromide-CH₂Cl₂ (36 mL), dropwise to maintain the reaction temperaturebetween −50 to −60° C. The gelatinous suspension is allowed to warm toRT and stir for 30 min. The reaction is cooled to 0° C., quenched withsatd NaHCO₃ and stirred for 30 min at RT. The mixture is extracted withCH₂Cl₂ (2×), the extracts combined, dried over Na₂SO₄, filtered andevaporated under reduced pressure to provide a crude solid, which waspurified by flash chromatography (SiO₂) eluting with a CH₂Cl₂-MeOHgradient to afford 1.13 g (76%) ofN-(6-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)acetamide as a beigesolid.

[0376] LC/MS: C₁₂H₁₅NO₂: m/z 206 (M+1)

[0377] C.2-(6-Acetylamino-5.6,7,8-tetrahydronaphthalen-2-yloxy)-2-methylpropionicacid tert-butyl ester.

[0378] Scheme 7. To a suspension ofN-(6-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)acetamide (0.439 g; 2.1mmol) in DMF (6 mL) is added Cs₂CO₃ (1.7 g; 5.2 mmol) and tert-butyl2-bromoisobutyrate (2.1 mL; 9.4 mmol) and the reaction mixture wasstirred at 100° C. for 18 h. The reaction was cooled to RT, diluted withEtOAc, washed with H₂O, brine, dried over Na₂SO₄, filtered, and thesolvent removed under reduced pressure to provide a crude oil, which waspurified by flash chromatography (SiO₂) eluting with a hexanes-EtOAcgradient to afford 0.51 g (69%) of2-(6-acetylamino-5,6,7,8-tetrahydronaphthalen-2-yloxy)-2-methylpropionicacid tert-butyl ester as an oil.

[0379]¹H NMR (300 MHz, CDCl₃): δ 6.89-6.92 (d, 1H), 6.58-6.65 (m, 2H),5.85-5.88 (m, 1H), 4.24-4.30 (m, 1H), 2.99-3.06 (dd, 1H), 2.76-2.86 (m,2H), 2.51-2.59 (dd, 1H), 2.04 (s, 2H), 1.98-2.02 (m, 1H), 1.74-1.79 (m,1H), 1.54 (s, 6H), 1.46 (s, 9H)

[0380] LC/MS: C₂₀H₂₉NO₄: m/z 292 (M+1)

[0381] The following compound was completed following Schemes 3 and 4and Steps I, J and K of Route 1, substituting reagents and adjustingreaction conditions as needed:

[0382] Compound 4.0 (0.0168 g; 23% for 2 steps; oil) was preparedfollowing Route 1 and Compound 1.0.

[0383] LC/MS: C₂₄H₂₇F₃N₂O₅: m/z 481 (M+1)

[0384] 2-{6-[3-(4-tert-Butylphenyl)1-ethylureido]-3-methoxy-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid.

[0385] Compound 1.6 (10 mg; oil) can be prepared by replacing4-trifluoromethoxyphenyl isocyanate with 4-tert-butylphenyl isocyanateand using Route 1, steps 1, J, and K and Schemes 4 and 10.

[0386] LC/MS: C₂₈H₃₈N₂O₄S: m/z 499 (M+1)

[0387]2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-fluoro-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid

[0388] Compound 1.7 (16 mg; 30% after 2 steps; white solid) can beprepared following Route 1, steps I, J, and K and Schemes 4 and 10.

[0389]¹H NMR (300 MHz, CDCl₃): δ 7.46-7.51 (m, 2H), 7.25-7.28 (d, 1H),7.17-7.20 (d, 2H), 6.92-6.95 (d, 1H), 4.43 (m, 1H), 3.42-3.49 (m, 2H),2.90-3.11 (m, 4H), 2.02-2.07 (m, 2H), 1.45 (s, 6H), 1.25-1.31 (t, 3H)

[0390] LC/MS: C₂₅H₂₉F₃N₂O₅S: m/z 515 (M+1)

[0391]2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-chloro-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid

[0392] Compound 1.8 (15 mg; 22% after 2 steps; white solid) can beprepared following Route 1, steps I, J, and K and Schemes 4 and 10.

[0393] LC/MS: C₂₅H₂₉F₃N₂O₅S: m/z 532 (M+1)

[0394]2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-bromo-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid

[0395] Compound 1.9 (55 mg; 43% for 2 steps; white solid) can beprepared following Route 1, steps I, J, and K and Schemes 4 and 10.

[0396]¹H NMR (300 MHz, CDCl₃): δ 7.45-7.48 (m, 3H), 7.36 (s, 1H),7.15-7.18 (d, 2H), 4.41-4.79 (m, 1H), 3.40-3.47 (m, 2H), 2.90-3.07 (m,4H), 2.01-2.03 (m, 2H), 1.45 (s, 6H), 1.24-1.29 (t, 3H)

[0397] LC/MS: C₂₅H₂₉F₃N₂O₅S: m/z 576 (M+1)

[0398]2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-methyl-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid

[0399] Compound 1.10 (73 mg; 26% for 2 steps; white solid) can beprepared following Route 1, steps 1, J, and K and Schemes 4 and 10.

[0400]¹H NMR (300 MHz, CDCl₃): δ 7.45-7.48 (m, 2H), 7.22 (s, 1H),7.15-7.18 (d, 2H), 7.02 (s, 1H), 4.41-4.79 (m, 1H), 3.40-3.47 (m, 2H),2.85-3.03 (m, 4H), 2.39 (s, 3H), 2.01-2.03 (m, 2H), 1.41 (s, 6H),1.24-1.29 (t, 3H)

[0401] LC/MS: C₂₅H₂₉F₃N₂O₅S: m/z 511 (M+1)

[0402]2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-trifluoromethoxy-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid

[0403] Compound 1.11 (118 mg; 58% for 2 steps; white solid) can beprepared following Route 1, steps 1, J, and K and Schemes 4 and 10.

[0404]¹H NMR (300 MHz, CDCl₃): δ 7.45-7.48 (d, 2H), 7.37 (s, 1H),7.12-7.18 (m, 3H), 4.44 (m, 1H), 3.43-3.48 (m, 2H), 2.97-3.21 (m, 4H),2.03-2.05 (m, 2H), 1.42 (s, 6H), 1.25-1.30 (t, 3H)

[0405] LC/MS: C₂₅H₂₉F₃N₂O₅S: m/z 580 (M+1)

[0406] 2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-phenyl-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionic acid

[0407] Compound 1.12 (118 mg; 58% for 2 steps; white solid) can beprepared following Route 1, steps I, J, and K and Schemes 4 and 10.

[0408]¹H NMR (300 MHz, CDCl₃): δ 7.45-7.48 (d, 2H), 7.29-7.38 (m, 6H),7.15-7.18 (d, 2H), 7.10 (s, 1H), 4.46 (m, 1H), 3.44-3.49 (m, 2H),2.98-3.06 (m, 4H), 2.04-2.06 (m, 2H), 1.26-1.30 (t, 3H), 1.14 (s, 6H)

[0409] LC/MS: C₂₅H₂₉F₃N₂O₅S: m/z 573 (M+1)

[0410]2-{6-[1-Ethyl-3-(4-hydroxyphenyl)ureido]-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid (Example 56)

[0411] 2-{6-[4-Aminophenyl)-1-ethylureido]-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid (Example 57)

[0412]2-[3-Chloro-6-(ethyl-p-tolyloxycarbonyl-amino)-5,6,7,8-tetrahydro-naphthaien-2-ylsulfanyl]-2-methyl-propionicacid tert-butyl ester.

[0413] To a mixture of2-(3-chloro-6-ethylamino-5,6,7,8-tetrahydro-naphthalen-2-ylsulfanyl)-2-methyl-propionicacid tert-butyl ester and borane complex (80 mg; 201 μmol), dissolved inCH₂Cl₂ (2 mL), at 0° C. is added p-tolyl chloroformate (351 L; 241μmol). The reaction was slowly warmed to RT and allowed to stir at RTfor 6 days. The solvent was removed under reduced pressure and the cruderesidue was purified by flash chromatography (SiO₂) eluting with ahexanes-EtoAc gradient to afford 30 mg (29%) of2-[3-chloro-6-(ethyl-p-tolyloxycarbonyl-amino)-5,6,7,8-tetrahydro-naphthalen-2-ylsulfanyl]-2-methyl-propionicacid tert-butyl ester as a clear oil.

[0414]¹H NMR (300 MHz, CDCl₃): δ 6.67-7.29 (m, 6H), 4.28 (m, 1H), 3.40(m, 2H), 2.87-2.97 (m, 4H), 2.33 (s, 3H), 1.89-2.06 (m, 2H), 1.39-1.46(m, 15H), 1.21-1.31 (m, 3H)

[0415] Compound 5.0 (23 mg; 59%) was prepared following Step M of Route2.

[0416]¹H NMR (300 MHz, CD₃OD): δ 6.96-7.34 (m, 6H), 4.27 (m, 1H), 3.49(m, 2H), 2.91-3.14 (m, 4H), 2.32 (s, 3H), 2.10 (m, 2H), 1.45 (m, 6H),1.28 (m, 3H)

[0417] LC/MS: C₂₄H₂₈ClNO₄S: m/z 462 (M+1)

[0418]2-{3-Chloro-6-[(4-chloro-phenoxycarbonyl)-ethyl-amino]-5,6,7,8-tetrahydro-naphthalen-2-ylsulfanyl}-2-methyl-propionicacid. Compound 5.1 (Example 59)

[0419] Compound 5.1 (34 mg; 35% for 2 steps; white solid) was preparedfollowing Route 5, substituting 4-chlorophenyl chloroformate for p-tolylchloroformate and Step M of Route 2.

[0420]¹H NMR (300 MHz, CD₃OD): δ 7.11-7.39 (m, 6H), 4.30 (m, 1H), 3.47(m, 2H), 2.91-3.15 (m, 4H), 2.06 (m, 2H), 1.45 (m, 6H), 1.28 (m, 3H)

[0421] LC/MS: C₂₃H₂₅Cl₂NO₄S: m/z 482 (M+1)

[0422]2-{6-[Ethyl-(4-trifluoromethoxy-phenoxycarbonyl)-amino]-5,6,7,8-tetrahydro-naphthalen-2-ylsulfanyl}-2-methyl-propionicacid.

[0423] Compound 5.2 can be prepared prepared following Route 5,substituting carbonic acid 1-chloro-ethyl ester 4-trifluoromethoxyphenyl ester for p-tolyl chlroroformate and Step M of Route 2.

[0424] Alternatively, compound 5.2 can be prepared using the followingprocedure:

[0425] A. Carbonic acid 1-chloro-ethyl ester 4-trifluoromethoxy-phenylester.

[0426] Scheme 1. A solution of 1-chloroethyl chloroformate (1.03 g; 7.20mmol) in CH₂Cl₂ (10 mL) was cooled to 0° C., trifluoromethoxyphenol(1.09 g; 6.0 mmol) and triethylamine were added, and the resultingsolution was warmed to RT. After stirred for 3 h, the reaction wasquenched with saturated NaHCO₃, and extracted with EtOAc (3 times). Thecombined organic extracts were washed with water, brine, dried overNa₂SO₄, and the solvent was removed under reduced pressure. The cruderesidue was purified by flash chromatography eluting with Hexane-EtOAc(10:1) to provide 1.54 g (90%) of carbonic acid 1-chloro-ethyl ester4-trifluoromethoxy-phenyl ester as a colorless oil.

[0427]¹H NMR (400 MHz, CDCl₃): δ 7.26 (m, 4H), 6.49 (q, 1H), 1.91 (d,3H)

[0428] B. Ethyl-(6-methoxy-1.2,3,4-tetrahydro-naphthalen-2-yl)-carbamicacid 4-trifluoromethoxy-phenyl ester

[0429] Scheme 1. To a mixture of 6-methoxy-2-tetralone (950 mg; 5.39mmol), 2 M of ethylamine in THF (5.4 mL; 10.78 mmol) and acetic acid(648 mg; 10.78 mmol) in CH₂Cl₂ (5 mL) was added sodiumtriacetoxyborohydride (2.29 g; 10.78 mmol). The reaction mixture wasstirred at RT for 3 h, then 1 N solution of NaOH was added, andextracted with ether (3 times). The combined organic extracts were driedover Na₂SO₄, and the solvent was removed under reduced pressure to givea light-yellow oil. This oil was added to a solution of carbonic acid1-chloro-ethyl ester 4-trifluoromethoxy-phenyl ester (1.23 g; 4.31 mmol)in toluene(8 mL), and the reaction mixture was stirred for 1 h at RTfollowed by 1 h at 90° C. The reaction was allowed to cool to RT,diluted with Et₂O and washed with 1 N of aqueous HCl and saturatedNaHCO₃. The organic extract was dried over Na₂SO₄, and the solvent wasremoved under reduced pressure. Flash chromatography of the residue witha gradient of hexane-CH₂Cl₂ gave 1.05 g (48%) ofethyl-(6-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-carbamic acid4-trifluoromethoxy-phenyl ester as a white solid.

[0430]¹H NMR (400 MHz, CDCl₃): δ 7.10-7.30 (m, 4H), 6.99 (d, 1H), 6.71(d, 1H), 6.64 (s, 1H), 4.33 (m, 1H), 3.77 (s, 3H), 3.41 (m, 2H), 2.93(m, 4H), 2.04 (m, 2H), 1.31 (m, 3H)

[0431] LC/MS: C₂₁H₂₃F₃NO₄: m/z 410 (M+1)

[0432] C. Ethyl-(6-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-carbamicacid 4-trifluoromethoxy-phenyl ester.

[0433] Scheme 1. A solution ofethyl-(6-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-carbamic acid4-trifluoromethoxy-phenyl ester (898.6 mg; 2.19 mmol) in anhydrousCH₂Cl₂ (8 mL) was cooled to −78° C., a 1.0 M solution of borontribromide-CH₂Cl₂ (6.57 mL, 6.57 mmol) was added slowly. Upon completionof the addition, the reaction mixture was allowed to warm to RT,quenched with MeOH (10 mL) and stirred for an additional 2 h. Thesolvents were evaporated, and the residue was purified by flashchromatography with hexane-EtOAc (2.5:1) to give 649.4 mg (75%) ofethyl-(6-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-carbamic acid4-trifluoromethoxy-phenyl ester as a white solid.

[0434]¹H NMR (300 MHz, CDCl₃): δ7.05-7.30 (m, 4H), 6.90 (m, 1H),7.41-7.60 (m, 2H), 5.05 (s, 1H), 4.30 (m, 1H), 3.41 (m, 2H), 2.90 (m,4H), 1.99 (m, 2H), 1.31 (m, 3H)

[0435] LC/MS: C₂₀H₂₁F₃NO₄: m/z 396 (M+1)

[0436] D.Ethyl-(6-triisopropvlsilanylsulfanyl-1,2,3,4-tetrahydro-naphthalen-2-yl)-carbamicacid 4-trifluoromethoxy-phenyl ester.

[0437] Scheme 1. A solution ofethyl-(6-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-carbamic acid4-trifluoromethoxy-phenyl ester (245.1 mg; 0.62 mmol) in anhydrousCH₂Cl₂ (3 mL) and THF (3 mL) was cooled to −30° C., triethylamine (216uL, 1.55 mmol) and triflic anhydride (125 uL, 0.74 mmol) weresuccessively added. The resulting mixture was stirred at RT for 2 h,then quenched with water, and extracted with Et₂O (3 times). Thecombined organic extracts were washed with water, brine, dried overNa₂SO₄, and the solvent was removed under reduced pressure. Flashchromatography of the residue with hexane-EtOAc (5:1) yielded 301.6 mg(92%) of the triflate. This triflate (279.8 mg; 0.53 mmol) andtetrakis(triphenylphosphine)palladium (61.2 mg; 0.053 mmol) were addedto a toluene solution generated from triisopropylsilanethiol (126 uL,0.58 mmol) and NaH (13.9 mg; 0.58 mmol) at RT. The resulting mixture wasvacuumed twice, and refluxed for 4 h, and concentrated under reducedpressure. Flash chromatography of the residue with hexane-EtOAc (10:1)afforded 261.8 mg (87%) ofethyl-(6-triisopropylsilanylsulfanyl-1,2,3,4-tetrahydro-naphthalen-2-yl)-carbamicacid 4-trifluoromethoxy-phenyl ester as a light-color oil.

[0438]¹H NMR (300 MHz, CDCl₃): δ 6.82-7.29(m, 7H), 4.32 (m, 1H), 3.40(m, 2H), 2.81-3.05 (m, 4H), 2.05 (m, 2H), 1.12-1.34 (m, 6H), 1.03-1.10(m, 18H)

[0439] LC/MS: C₂₉H₄₁F₃NO₃SSi: m/z 568 (M+1)

[0440] E.2-{6-[Ethyl-(4-trfluoromethoxy-phenoxycarbonyl)-amino]-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methyl-propionicacid tert-butyl ester.

[0441] Scheme 1. A solution ofethyl-(6-triisopropylsilanylsulfanyl-1,2,3,4-tetrahydro-naphthalen-2-yl)-carbamicacid 4-trifluoromethoxy-phenyl ester (260.0 mg; 0.46 mmol) andtert-butyl □-bromoisobutylrate (130 uL, 0.69 mmol) in anhydrous THF (2mL) was cooled to 0° C., a 1.0 M solution of TBAF (690 uL, 0.69 mmol)was added, then the reaction was warmed to RT, stirred for 1 h, and thendiluted with water, extracted with Et₂O (3 times). The combined organicextracts were dried over Na₂SO₄, and the solvent removed under reducedpressure. The crude residue was purified by flash chromatography elutingwith Hexane-EtOAc (7:1) to provide 229.2 mg (90%) of2-{6-[ethyl-(4-trifluoromethoxy-phenoxycarbonyl)-amino]-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methyl-propionicacid tert-butyl ester as a light-color oil.

[0442]¹H NMR (300 MHz, CDCl₃): δ 6.95-7.28 (m, 7H), 4.34 (m, 1H), 3.41(m, 2H), 2.96 (m, 2H), 2.91 (m, 2H), 3.41 (m, 2H), 2.06 (m, 2H), 1.44(s, 6H), 1.42 (s, 9H), 1.28 (m, 3H)

[0443] LC/MS: C₂₈H₃₄F₃NO₅SNa: m/z 576 (M+Na)

[0444] F.2-{6-[Ethyl-(4-trifluoromethoxy-phenoxycarbonyl)-amino]-5,6,7,8-tetrahydro-naihthalen-2-ylsulfanyl}-2-methyl-propionicacid.

[0445] Scheme 1. A solution of2-{6-[ethyl-(4-trifluoromethoxy-phenoxycarbonyl)-amino]-5,6,7,8-tetrahydro-naphthalen-2-ylsulfanyl}-2-methyl-propionicacid (120.8 mg; 0.22 mmol) in CH₂Cl₂ (4 mL) was cooled to −78° C., andtrifluoroacetic acid (4 mL) was added slowly. The reaction mixture wasallowed to warm to RT, and stirred for 1.5 h. The solvents were thenevaporated, and the residue was purified by flash chromatography withCH₂Cl₂-MeOH (94:6) to give2-{6-[ethyl-(4-trifluoromethoxy-phenoxycarbonyl)-amino]-5,6,7,8-tetrahydro-naphthalen-2-ylsulfanyl}-2-methyl-propionicacid as a white solid.

[0446]¹H NMR (400 MHz, CDCl₃): δ 6.96-7.28 (m, 7H), 4.30 (m, 1H), 3.39(m, 2H), 2.85-3.10 (m, 4H), 2.06 (m, 2H), 1.49 (s, 6H), 1.28 (m, 3H)

[0447] LC/MS: C₂₄H₂₇F₃NO₅S: m/z 498 (M+1)

[0448] D. Formulation and Administration

[0449] The present compounds are PPAR alpha agonists and are thereforeuseful in treating or inhibiting the progression of PPAR alpha mediateddiseases and conditions, such as diabetes, and complications thereof,such as neuropathy, nephropathy, and retinopathy.

[0450] The invention features a method for treating a subject with aPPAR alpha-mediated disease, said method comprising administering to thesubject a therapeutically effective amount of a pharmaceuticalcomposition comprising a compound of the invention. The invention alsoprovides a method for treating or inhibiting the progression of diabetesor impaired glucose tolerance in a subject, wherein the method comprisesadministering to the subject a therapeutically effective amount of apharmaceutical composition comprising a compound of the invention.

[0451] The compounds of the present invention may be formulated intovarious pharmaceutical forms for administration purposes. To preparethese pharmaceutical compositions, an effective amount of a particularcompound, in base or acid addition salt form, as the active ingredientis intimately mixed with a pharmaceutically acceptable carrier.

[0452] A carrier may take a wide variety of forms depending on the formof preparation desired for administration. These pharmaceuticalcompositions are desirably in unitary dosage form suitable, preferably,for oral administration or parenteral injection. For example, inpreparing the compositions in oral dosage form, any of the usualpharmaceutical media may be employed. These include water, glycols,oils, alcohols and the like in the case of oral liquid preparations suchas suspensions, syrups, elixirs and solutions; or solid carriers such asstarches, sugars, kaolin, lubricants, binders, disintegrating agents andthe like in the case of powders, pills, capsules and tablets. In view oftheir ease in administration, tablets and capsules represent the mostadvantageous oral dosage unit form, in which case solid pharmaceuticalcarriers are generally employed. For parenteral compositions, thecarrier will usually comprise sterile water, at least in large part,though other ingredients, for example, to aid solubility, may beincluded. Injectable solutions, for example, may be prepared in whichthe carrier comprises saline solution, glucose solution or a mixture ofsaline and glucose solution. Injectable suspensions may also be preparedin which case appropriate liquid carriers, suspending agents and thelike may be employed. In the compositions suitable for percutaneousadministration, the carrier optionally comprises a penetration enhancingagent and/or a suitable wetting agent, optionally combined with suitableadditives of any nature in minor proportions, which additives do notcause a significant deleterious effect to the skin. Such additives mayfacilitate the administration to the skin and/or may be helpful forpreparing the desired compositions. These compositions may beadministered in various ways, e.g., as a transdermal patch, as aspot-on, as an ointment. Acid addition salts of the compounds of formulaI, due to their increased water solubility over the corresponding baseform, are more suitable in the preparation of aqueous compositions.

[0453] It is especially advantageous to formulate the aforementionedpharmaceutical compositions in dosage unit form for ease ofadministration and uniformity of dosage. Dosage unit form as used in thespecification herein refers to physically discrete units suitable asunitary dosages, each unit containing a predetermined quantity of activeingredient calculated to produce the desired therapeutic effect inassociation with the required pharmaceutical carrier. Examples of suchdosage unit forms are tablets (including scored or coated tablets),capsules, pills, powder packets, wafers, injectable solutions orsuspensions, teaspoonfuls, tablespoonfuls and the like, and segregatedmultiples thereof.

[0454] Pharmaceutically acceptable acid addition salts include thetherapeutically active non-toxic acid addition salt forms which thedisclosed compounds are able to form. The latter can conveniently beobtained by treating the base form with an appropriate acid. Appropriateacids comprise, for example, inorganic acids such as hydrohalic acids,e.g. hydrochloric or hydrobromic acid; sulfuric; nitric; phosphoric andthe like acids; or organic acids such as, for example, acetic,propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic,maleic, fumaric, malic, tartaric, citric, methanesulfonic,ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic,p-aminosalicylic, palmoic and the like acids. The term addition saltalso comprises the solvates which the disclosed componds, as well as thesalts thereof, are able to form. Such solvates are for example hydrates,alcoholates and the like. Conversely the salt form can be converted bytreatment with alkali into the free base form.

[0455] Stereoisomeric forms define all the possible isomeric forms whichthe compounds of formula (I) may possess. Unless otherwise mentioned orindicated, the chemical designation of compounds denotes the mixture ofall possible stereochemically isomeric forms, said mixtures containingall diastereomers and enantiomers of the basic molecular structure. Morein particular, stereogenic centers may have the (R)- or(S)-configuration; substituents on bivalent cyclic saturated radicalsmay have either the cis-or trans-configuration. The inventionencompasses stereochemically isomeric forms including diastereoisomers,as well as mixtures thereof in any proportion of the disclosedcompounds. The disclosed compounds may also exist in their tautomericforms. Such forms although not explicitly indicated in the above andfollowing formulae are intended to be included within the scope of thepresent invention. For example, in compound 2.1 or Example 3, there is achiral center on the C-2 of the indane ring. For this compound, the (S)isomer is more active than the (R) isomer.

[0456] E. Use

[0457] Those of skill in the treatment of disorders or conditionsmediated by the PPAR alpha could easily determine the effective dailyamount from the test results presented hereinafter and otherinformation. In general it is contemplated that a therapeuticallyeffective dose would be from 0.001 mg/kg to 5 mg/kg body weight, morepreferably from 0.01 mg/kg to 0.5 mg/kg body weight. It may beappropriate to administer the therapeutically effective dose as two,three, four or more sub-doses at appropriate intervals throughout theday. Said sub-doses may be formulated as unit dosage forms, for example,containing 0.05 mg to 250 mg or 750 mg, and in particular 0.5 to 50 mgof active ingredient per unit dosage form. Examples include 2 mg, 4 mg,7 mg, 10 mg, 15 mg, 25 mg, and 35 mg dosage forms. Compounds of theinvention may also be prepared in time-release or subcutaneous ortransdermal patch formulations. Disclosed compound may also beformulated as a spray or other topical or inhalable formulations.

[0458] The exact dosage and frequency of administration depends on theparticular compound of formula (I) used, the particular condition beingtreated, the severity of the condition being treated, the age, weightand general physical condition of the particular patient as well asother medication the patient may be taking, as is well known to thoseskilled in the art. Furthermore, it is evident that said effective dailyamount may be lowered or increased depending on the response of thetreated patient and/or depending on the evaluation of the physicianprescribing the compounds of the instant invention. The effective dailyamount ranges mentioned herein are therefore only guidelines.

[0459] The next section includes detailed information relating to theuse of the disclosed compounds and compositions.

[0460] The compounds of the present invention are pharmaceuticallyactive, for example, as PPAR alpha agonists. According to one aspect ofthe invention, the compounds are preferably selective PPAR alphaagonists, having an activity index (e.g., PPAR alpha potency over PPARgamma potency) of 10 or more, and preferably 15, 25, 30, 50 or 100 ormore.

[0461] PPAR alpha agonists are useful for the treatment, prevention, orinhibiting the progression of one or more of the following conditions ordiseases: Type II diabetes, impaired glucose tolerance, impaired fastingglucose, neuropathy, nephropathy, retinopathy, insulin resistance,hyperglycemia, and hyperinsulinemia.

[0462] Combination Therapy

[0463] The compounds of the present invention may be used in combinationwith other pharmaceutically active agents. These agents includeanti-diabetic agents, such as Metformin, insulin, and insulinsensitizers (such as TZD's; blood-pressure lowering agents; lipidlowering agents; and Acrp30 or Adiponectin modulators such as Famoxin.

[0464] Methods are known in the art for determining effective doses fortherapeutic and prophylactic purposes for the disclosed pharmaceuticalcompositions or the disclosed drug combinations, whether or notformulated in the same composition. For therapeutic purposes, the term“jointly effective amount” as used herein, means that amount of eachactive compound or pharmaceutical agent, alone or in combination, thatelicits the biological or medicinal response in a tissue system, animalor human that is being sought by a researcher, veterinarian, medicaldoctor or other clinician, which includes alleviation of the symptoms ofthe disease or disorder being treated. For prophylactic purposes (i.e.,inhibiting the onset or progression of a disorder), the term “jointlyeffective amount” refers to that amount of each active compound orpharmaceutical agent, alone or in combination, that treats or inhibitsin a subject the onset or progression of a disorder as being sought by aresearcher, veterinarian, medical doctor or other clinician. Thus, thepresent invention provides combinations of two or more drugs wherein,for example, (a) each drug is administered in an independentlytherapeutically or prophylactically effective amount; (b) at least onedrug in the combination is administered in an amount that issub-therapeutic or sub-prophylactic if administered alone, but istherapeutic or prophylactic when administered in combination with thesecond or additional drugs according to the invention; or (c) both drugsare administered in an amount that is sub-therapeutic orsub-prophylactic if administered alone, but are therapeutic orprophylactic when administered together.

[0465] Anti-diabetic agents include thiazolidinedione andnon-thiazolidinedione insulin sensitizers, which decrease peripheralinsulin resistance by enhancing the effects of insulin at target organsand tissues.

[0466] Some of the following agents are known to bind and activate thenuclear receptor peroxisome proliferator-activated receptor-gamma (PPAR)which increases transcription of specific insulin-responsive genes.Examples of PPAR-gamma agonists are thiazolidinediones such as:

[0467] (1) rosiglitazone (2,4-thiazolidinedione,5-((4-(2-(methyl-2-pyridinylamino) ethoxy) phenyl) methyl)-,(Z)-2-butenedioate (1:1) or 5-((4-(2-(methyl-2-pyridinylamino) ethoxy)phenyl) methyl)-2,4-thiazolidinedione, known as AVANDIA; also known asBRL 49653, BRL 49653C, BRL 49653c, SB 210232, or rosiglitazone maleate);

[0468] (2) pioglitazone (2,4-thiazolidinedione,5-((4-(2-(5-ethyl-2-pyridinyl) ethoxy) phenyl) methyl)-,monohydrochloride, (+)-or 5-((4-(2-(5-ethyl-2-pyridyl) ethoxy) phenyl)methy)-2,4-thiazolidinedione, known as ACTOS, ZACTOS, or GLUSTIN; alsoknown as AD 4833, U 72107, U 72107A, U 72107E, pioglitazonehydrochloride (USAN));

[0469] (3) troglitazone(5-((4-((3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy) phenyl) methyl)-2,4-thiazolidinedione, known as NOSCAL,REZULIN, ROMOZIN, or PRELAY; also known as Cl 991, CS 045, GR 92132, GR92132×);

[0470] (4) isaglitazone((+)-5-[[6-[(2-fluorophenyl)methoxy]-2-naphthalenyl]methyl]-2,4-thiazolidinedioneor 5-((6-((2-fluorophenyl) methoxy)-2-naphthalenyl)methyl-2,4-thiazolidinedione or 5-(6-(2-fluorobenzyloxy)naphthalen-2-ylmethyl) thiazolidine-2,4-dione, also known as MCC-555 orneoglitazone); and

[0471] (5) 5-BTZD.

[0472] Additionally, the non-thiazolidinediones that act as insulinsensitizing agents include, but are not limited to:

[0473] (1) JT-501 (JTT 501, PNU-1827, PNU-716-MET-0096, or PNU 182716:isoxazolidine-3,5-dione, 4-((4-(2-phenyl-5-methyl)-1,3-oxazolyl)ethylphenyl-4) methyl-);

[0474] (2) KRP-297(5-(2,4-dioxothiazolidin-5-ylmethyl)-2-methoxy-N-(4-(trifluoromethyl)benzyl) benzamide or 5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl) phenyl) m ethyl) benzamide);and

[0475] (3) Farglitazar (L-tyrosine,N-(2-benzoylphenyl)-o-(2-(5-methyl-2-phenyl-4-oxazolyl) ethyl)-orN-(2-benzoylphenyl)-O-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-L-tyrosine, or GW2570 or GI-262570).

[0476] Other agents have also been shown to have PPAR modulator activitysuch as PPAR gamma, SPPAR gamma, and/or PPAR delta/gamma agonistactivity. Examples are listed below:

[0477] (1) AD 5075;

[0478] (2) R 119702 ((+−)-5-(4-(5-Methoxy-1H-benzimidazol-2-ylmethoxy)benzyl) thiazolin-2,4-dione hydrochloride, or CI 1037 or CS 011);

[0479] (3) CLX-0940 (peroxisome proliferator-activated receptor alphaagonist/peroxisome proliferator-activated receptor gamma agonist);

[0480] (4) LR-90 (2,5,5-tris (4-chlorophenyl)-1,3-dioxane-2-carboxylicacid, PPARdelta/γ agonist);

[0481] (5) Tularik (PPARFγ agonist);

[0482] (6) CLX-0921 (PPARγ agonist);

[0483] (7) CGP-52608 (PPAR agonist);

[0484] (8) GW409890 (PPAR agonist);

[0485] (9) GW-7845 (PPAR agonist);

[0486] (10) L-764406 (PPAR agonist);

[0487] (11) LG-101280 (PPAR agonist);

[0488] (12) LM-4156 (PPAR agonist);

[0489] (13) R is a rest at (CT-112);

[0490] (14) YM 440 (PPAR agonist);

[0491] (15) AR-H049020 (PPAR agonist);

[0492] (16) GW 0072 (4-(4-((2S,5S)-5-(2-(bis (phenylmethyl)amino)-2-oxoethyl)-2-heptyl-4-oxo-3-thiazo lidinyl) butyl) benzoicacid);

[0493] (17) GW 409544 (GW-544 or GW-409544);

[0494] (18) NN 2344 (DRF 2593);

[0495] (19) NN 622 (DRF 2725);

[0496] (20) AR-H039242 (AZ-242);

[0497] (21) GW 9820 (fibrate);

[0498] (22) GW 1929 (N-(2-benzoylphenyl)-O-(2-(methyl-2-pyridinylamino)ethyl)-L-tyrosine, known as GW 2331, PPAR alpha/γ agonist);

[0499] (23) SB 219994 ((S)-4-(2-(2-benzoxazolylmethylamino)ethoxy)-alpha-(2,2,2-trifluoroethoxy) benzenepropanoic acid or3-(4-(2-(N-(2-benzoxazolyl)-N-methylamino) ethoxy) phenyl)-2 (S)-(2,2,2-trifluoroethoxy) propionic acid or benzenepropanoic acid,4-(2-(2-benzoxazolylmethylamino) ethoxy)-alpha-(2,2,2-trifluoroethoxy)-,(alphaS)-, PPARalpha/γ agonist);

[0500] (24) L-796449 (PPAR alpha/γ agonist);

[0501] (25) Fenofibrate (Propanoic acid,2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester, known asTRICOR, LIPCOR, LIPANTIL, LIPIDIL MICRO PPAR alpha agonist);

[0502] (26) GW-9578 (PPAR alpha agonist);

[0503] (27) GW-2433 (PPAR alpha/γ agonist);

[0504] (28) GW-0207 (PPARγ agonist);

[0505] (29) LG-100641 (PPARγ agonist);

[0506] (30) LY-300512 (PPARγ agonist);

[0507] (31) NID525-209 (NID-525);

[0508] (32) VDO-52 (VDO-52);

[0509] (33) LG 100754 (peroxisome proliferator-activated receptoragonist);

[0510] (34) LY-510929 (peroxisome proliferator-activated receptoragonist);

[0511] (35) bexarotene(4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthalenyl) ethenyl)benzoic acid, known as TARGRETIN, TARGRETYN, TARGREXIN; also known asLGD 1069, LG 100069, LG 1069, LDG 1069, LG 69, RO 264455); and

[0512] (36) GW-1536 (PPAR alpha/γ agonist).

[0513] (B) Other insulin sensitizing agents include, but are not limitedto:

[0514] (1) INS-1 (D-chiro inositol or D-1, 2, 3, 4, 5,6-hexahydroxycyclohexane);

[0515] (2) protein tyrosine phosphatase 1 B (PTP-1B) inhibitors;

[0516] (3) glycogen synthase kinase-3 (GSK3) inhibitors;

[0517] (4) beta 3 adrenoceptor agonists such as ZD 2079((R)-N-(2-(4-(carboxymethyl) phenoxy) ethyl)-N-(2-hydroxy-2-phenethyl)ammonium chloride, also known as ICI D 2079) or AZ 40140;

[0518] (5) glycogen phosphorylase inhibitors;

[0519] (6) fructose-1,6-bisphosphatase inhibitors;

[0520] (7) chromic picolinate, vanadyl sulfate (vanadium oxysulfate);

[0521] (8) KP 102 (organo-vanadium compound);

[0522] (9) chromic polynicotinate;

[0523] (10) potassium channel agonist NN 414;

[0524] (11) YM 268 (5,5′-methylene-bis (1,4-phenylene) bismethylenebis(thiazolidine-2,4-dione);

[0525] (12) TS 971;

[0526] (13) T 174((+−)-5-(2,4-dioxothiazolidin-5-ylmethyl)-2-(2-naphthylmethyl)benzoxazole);

[0527] (14) SDZ PGU 693 ((+)-trans-2 (S-((4-chlorophenoxy)methyl)-7alpha-(3,4-dichlorophenyl) tetrahydropyrrolo (2,1-b) oxazol-5(6H)-one);

[0528] (15) S 15261 ((−)-4-(2-((9H-fluoren-9-ylacetyl) amino) ethyl)benzoic acid 2-((2-methoxy-2-(3-(trifluoromethyl) phenyl) ethyl) amino)ethyl ester);

[0529] (16) AZM 134 (Alizyme);

[0530] (17) ARIAD;

[0531] (18) R 102380;

[0532] (19) PNU 140975 (1-(hydrazinoiminomethyl) hydrazino) acetic acid;

[0533] (20) PNU 106817 (2-(hydrazinoiminomethyl) hydrazino) acetic acid;

[0534] (21) NC 2100 (5-((7-(phenylmethoxy)-3-quinolinyl)methyl)-2,4-thiazolidinedione;

[0535] (22) MXC 3255;

[0536] (23) MBX 102;

[0537] (24) ALT 4037;

[0538] (25) AM 454;

[0539] (26) JTP 20993 (2-(4-(2-(5-methyl-2-phenyl-4-oxazolyl) ethoxy)benzyl)-malonic acid dimethyl diester);

[0540] (27) Dexlipotam (5 (R)-(1,2-dithiolan-3-yl) pentanoic acid, alsoknown as (R)-alpha lipoic acid or (R)-thioctic acid);

[0541] (28) BM 170744 (2,2-Dichloro-12-(p-chlorophenyl) dodecanoicacid);

[0542] (29) BM 152054 (5-(4-(2-(5-methyl-2-(2-thienyl) oxazol-4-yl)ethoxy) benzothien-7-ylmethyl) thiazolidine-2,4-dione);

[0543] (30) BM 131258 (5-(4-(2-(5-methyl-2-phenyloxazol-4-yl) ethoxy)benzothien-7-ylmethyl) thiazolidine-2,4-dione);

[0544] (31) CRE 16336 (EML 16336);

[0545] (32) HQL 975 (3-(4-(2-(5-methyl-2-phenyloxazol-4-yl) ethoxy)phenyl)-2 (S)-(propylamino) propionic acid);

[0546] (33) DRF 2189 (5-((4-(2-(1-Indolyl) ethoxy) phenyl) methyl)thiazolidine-2,4-dione);

[0547] (34) DRF 554158;

[0548] (35) DRF-NPCC;

[0549] (36) CLX 0100, CLX 0101, CLX 0900, or CLX 0901;

[0550] (37) IkappaB Kinase (IKK B) Inhibitors (38) mitogen-activatedprotein kinase (MAPK) inhibitors p38 MAPK Stimulators

[0551] (39) phosphatidyl-inositide triphosphate

[0552] (40) insulin recycling receptor inhibitors

[0553] (41) glucose transporter 4 modulators

[0554] (42) TNF-α antagonists

[0555] (43) plasma cell differentiation antigen-1 (PC-1) Antagonists

[0556] (44) adipocyte lipid-binding protein (ALBP/aP2) inhibitors

[0557] (45) phosphoglycans

[0558] (46) Galparan;

[0559] (47) Receptron;

[0560] (48) islet cell maturation factor;

[0561] (49) insulin potentiating factor (IPF or insulin potentiatingfactor-1);

[0562] (50) somatomedin C coupled with binding protein (also known asIGF-BP3, IGF-BP3, SomatoKine);

[0563] (51) Diab II (known as V-41A1) or Glucanin, produced by BiotechHoldings Ltd. or Volque Pharmaceutical;

[0564] (52) glucose-6 phosphatase inhibitors;

[0565] (53) fatty acid glucose transport protein;

[0566] (54) glucocorticoid receptor antagonists; and

[0567] (55) glutamine:fructose-6-phosphate amidotransferase (GFAT)modulators.

[0568] (C) Biguanides, which decrease liver glucose production andincreases the uptake of glucose. Examples include Metformin such as:

[0569] (1) 1,1-dimethylbiguanide (e.g., Metformin-DepoMed,Metformin-Biovail Corporation, or METFORMIN GR (Metformin gastricretention polymer)); and

[0570] (2) Metformin hydrochloride (N,N-dimethylimidodicarbonimidicdiamide monohydrochloride, also known as LA 6023, BMS 207150,GLUCOPHAGE, or GLUCOPHAGE XR.

[0571] (D) Alpha-glucosidase inhibitors, which inhibitalpha-glucosidase. Alpha-glucosidase converts fructose to glucose,thereby delaying the digestion of carbohydrates. The undigestedcarbohydrates are subsequently broken down in the gut, reducing thepost-prandial glucose peak. Examples include, but are not limited to:

[0572] (1) acarbose (D-glucose, O-4,6-dideoxy-4-(((1S-(1alpha,4alpha,5beta,6alpha))-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl)amino)-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-,also known as AG-5421, Bay-g-542, BAY-g-542, GLUCOBAY, PRECOSE, GLUCOR,PRANDASE, GLUMIDA, or ASCAROSE);

[0573] (2) Miglitol (3,4,5-piperidinetriol,1-(2-hydroxyethyl)-2-(hydroxymethyl)-, (2R (2alpha, 3beta, 4alpha,5beta))-or(2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl-3,4,5-piperidinetriol,also known as BAY 1099, BAY M 1099, BAY-m⁻¹⁰⁹⁹, BAYGLITOL, DIASTABOL,GLYSET, MIGLIBAY, MITOLBAY, PLUMAROL);

[0574] (3) CKD-711(0-4-deoxy-4-((2,3-epoxy-3-hydroxymethyl-4,5,6-trihydroxycyclohexane-1-yl)amino)-alpha-b-glucopyranosyl-(1-4)-alpha-D-glucopyranosyl-(1-4)-D-glucopyranose);

[0575] (4) emiglitate(4-(2-((2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)-1-piperidinyl)ethoxy) benzoic acid ethyl ester, also known as BAY o 1248 or MKC 542);

[0576] (5) MOR 14 (3,4,5-piperidinetriol, 2-(hydroxymethyl)-1-methyl-,(2R-(2alpha,3beta,4alpha,5beta))-, also known asN-methyldeoxynojirimycin or N-methylmoranoline); and

[0577] (6) Voglibose (3,4-dideoxy-4-((2-hydroxy-1-(hydroxymethyl) ethyl)amino)-2-C-(hydroxymethyl)-D-epi-inositol orD-epi-inositol,3,4-dideoxy-4-((2-hydroxy-1-(hydroxymethyl) ethyl)amino)-2-C-(hydroxymethyl)-, also known as A 71100, AO 128, BASEN,GLUSTAT, VOGLISTAT.

[0578] (E) Insulins include regular or short-acting,intermediate-acting, and long-acting insulins, non-injectable or inhaledinsulin, tissue selective insulin, glucophosphokinin (D-chlroinositol),insulin analogues such as insulin molecules with minor differences inthe natural amino acid sequence and small molecule mimics of insulin(insulin mimetics), and endosome modulators. Examples include, but arenot limited to:

[0579] (1) Biota;

[0580] (2) LP 100;

[0581] (3) (SP-5-21)-oxobis (1-pyrrolidinecarbodithioato-S, S′)vanadium,

[0582] (4) insulin aspart (human insulin (28B-L-aspartic acid) orB28-Asp-insulin, also known as insulin X14, INA-X14, NOVORAPID, NOVOMIX,or NOVOLOG);

[0583] (5) insulin detemir (Human29B-(N-6-(1-oxotetradecyl)-L-lysine)-(1A-21A), (1B-29B)-Insulin or NN304);

[0584] (6) insulin lispro (“28B-L-lysine-29B-L-proline human insulin, orLys(B28), Pro(B29) human insulin analog, also known as lys-pro insulin,LY 275585, HUMALOG, HUMALOG MIX 75/25, or HUMALOG MIX 50/50);

[0585] (7) insulin glargine (human (A21-glycine, B31-arginine,B32-arginine) insulin HOE 901, also known as LANTUS, OPTISULIN);

[0586] (8) Insulin Zinc Suspension, extended (Ultralente), also known asHUMULIN U or ULTRALENTE;

[0587] (9) Insulin Zinc suspension (Lente), a 70% crystalline and 30%amorphous insulin suspension, also known as LENTE ILETIN II, HUMULIN L,or NOVOLIN L;

[0588] (10) HUMULIN 50/50 (50% isophane insulin and 50% insulininjection);

[0589] (11) HUMULIN 70/30 (70% isophane insulin NPH and 30% insulininjection), also known as NOVOLIN 70/30, NOVOLIN 70/30 PenFill, NOVOLIN70/30 Prefilled;

[0590] (12) insulin isophane suspension such as NPH ILETIN II, NOVOLINN, s5 NOVOLIN N PenFill, NOVOLIN N Prefilled, HUMULIN N;

[0591] (13) regular insulin injection such as ILETIN II Regular, NOVOLINR, VELOSULIN BR, NOVOLIN R PenFill, NOVOLIN R Prefilled, HUMULIN R, orRegular U-500 (Concentrated);

[0592] (14) ARIAD;

[0593] (15) LY 197535;

[0594] (16) L-783281; and

[0595] (17) TE-17411.

[0596] (F) Insulin secretion modulators such as:

[0597] (1) glucagon-like peptide-1 (GLP-1) and its mimetics;

[0598] (2) glucose-insulinotropic peptide (GIP) and its mimetics;

[0599] (3) exendin and its mimetics;

[0600] (4) dipeptyl protease (DPP or DPPIV) inhibitors such as

[0601] (4a) DPP-728 or LAF 237(2-pyrrolidinecarbonitrile,1-(((2-((5-cyano-2-pyridinyl) amino) ethyl)amino) acetyl), known as NVP-DPP-728, DPP-728A, LAF-237);

[0602] (4b) P 3298 or P32/98 (di-(3N-((2S,3S)-2-amino-3-methyl-pentanoyl)-1,3-thiazolidine) fumarate);

[0603] (4c) TSL 225(tryptophyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid);

[0604] (4d) Valine pyrrolidide (valpyr);

[0605] (4e) 1-aminoalkylisoquinolinone-4-carboxylates and analoguesthereof;

[0606] (4f) SDZ 272-070 (1-(L-Valyl) pyrrolidine);

[0607] (4g) TMC-2A, TMC-2B, or TMC-2C;

[0608] (4h) Dipeptide nitriles (2-cyanopyrrolodides);

[0609] (4i) CD26 inhibitors; and

[0610] (4j) SDZ 274-444;

[0611] (5) glucagon antagonists such as AY-279955; and

[0612] (6) amylin agonists which include, but are not limited to,pramlintide (AC-137, Symlin, tripro-amylin or pramlintide acetate).

[0613] The present compounds may also increase insulin sensitivity witha smaller increase in body weight than that found with the use ofexisting PPAR gamma agonists. Oral anti-diabetic agents may includeinsulin, sulfonylureas, biguanides, meglitinides, AGI's, PPAR alphaagonists, and PPAR gamma agonists, and dual PPAR alpha/gamma agonists.

[0614] PPAR alpha agonists are useful for the treatment, prevention, orinhibiting the progression of one or more of the following conditions ordiseases: phase I hyperlipidemia, pre-clinical hyperlipidemia, phase IIhyperlipidemia, hypertension, coronary artery disease (CAD), andhypertriglyceridemia. Preferred compounds of the invention are useful inlowering serum levels of low-density lipoproteins (LDL), IDL, and/orsmall-density LDL and other atherogenic molecules, or molecules thatcause atherosclerotic or dyslipidemic complications, thereby reducingcardiovascular complications. Preferred compounds also are useful inelevating levels of high-density lipoproteins (HDL), in lowering levelsof triglycerides, LDL, and/or free fatty acids. It is also desirable tolower FPG/HbA1c.

[0615] As PPAR alpha agonists, the compounds of the invention may bemore potent and efficacious for lowering triglycerides than knownfibrates. The present compounds also may increase fat and/or lipidmetabolism, providing a method for losing weight, losing fat weight,lowering body mass index, lowering lipids (such as loweringtriglycerides), or treating obesity or the condition of beingoverweight. Examples of lipid lowering agents include bile acidsequestrants, fibric acid derivatives, nicotinic acid, and HMGCoAreductase inhibitors. Specific examples include statins such asLIPITOR™, ZOCOR™, PRAVACHOL™, LESCOL™, and MEVACOR™, and pitavastatin(nisvastatin) (Nissan, Kowa Kogyo, Sankyo, Novartis) and extendedrelease forms thereof, such as ADX-159 (extended release lovastatin), aswell as Colestid, Locholest, Questran, Atromid, Lopid, and Tricor.

[0616] Examples of blood pressure lowering agents includeanti-hypertensive agents, such as angiotensin-converting enzyme (ACE)inhibitors (Accupril, Altace, Captopril, Lotensin, Mavik, Monopril,Prinivil, Univasc, Vasotec, and Zestril), adrenergic blockers (such asCardura, Dibenzyline, Hylorel, Hytrin, Minipress, and Minizide)alph/beta adrenergic blockers (such as Coreg, Normodyne, and Trandate),calcium channel blockers (such as Adalat, Calan, Cardene, Cardizem,Covera-HS, Dilacor, DynaCirc, Isoptin, Nimotop, Norvace, Plendil,Procardia, Procardia XL, Sula, Tiazac, Vascor, and Verelan), diuretics,antiotensin II receptor antagonists (such as Atacand, Avapro, Cozaar,and Diovan), beta adrenergic blockers (such as Betapace, Blocadren,Brevibloc, Cartrol, Inderal, Kerlone, Lavatol, Lopressor, Sectral,Tenormin, Toprol-XL, and Zebeta), vasodilators (such as Deponit,Dilatrate, SR, Imdur, Ismo, Isordil, Isordil Titradose, Monoket,Nitro-Bid, Nitro-Dur, Nitrolingual Spray, Nitrostat, and Sorbitrate),and combinations thereof (such as Lexxel, Lotrel, Tarka, Teczem,Lotensin HCT, Prinzide, Uniretic, Vaseretic, Zestoretic).

F. EXAMPLES

[0617] The following chemical and biological examples are intended toillustrate, not limit, the invention.

2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid EC₅₀=0.023 μM

[0618]

2-{2-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid EC₅₀=0.027 μM

[0619]

(S)-2-{2-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid EC₅₀=0.0002 μM

[0620]

2-{2-[1-Ethyl-3-(4-trifluoromethylsulfanylphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid EC₅₀=0.037 μM

[0621]

2-Methyl-2-{2-[1-pentyl-3-(4-trifluoromethylsulfanylphenyl)ureido]indan-5-ylsulfanyl}propionicacid EC₅₀=0.053 μM

[0622]

2-{2-[1-Ethyl-3-(4-isopropylphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid EC₅₀=0.056 μM

[0623]

2-{2-[3-(4-Dimethylaminophenyl)-1-ethylureido]indan-5-ylsulfanyl}-2-methylpropionicacid EC₅₀=0.075 μM

[0624]

2-Methyl-2-{2-[1-pentyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionic acid EC₅₀=0.073 μM

[0625]

2-{2-[3-(4-Dimethylaminophenyl)-1-pentylureido]indan-5-ylsulfanyl}-2-methylpropionic acid EC₅₀=0.131 μM

[0626]

2-{2-[3-(4-Isopropylphenyl)-1-(3-pentyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid EC₅₀=0.165 μM

[0627]

2-{2-[3-(4-tert-Butylphenyl)-1-(3-pentyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid EC₅₀=0.173 μM

[0628]

[0629]2-[2-(3-(Biphenyl-4-yl-1-pentylureido)indan-5-ylsulfanyl]-2-methylpropionicacid

EC₅₀=0.183 μM

[0630]

2-{2-[3-(4-Isopropylphenyl)-1-(3-hexyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid EC₅₀=0.184 μM

[0631]

2-Methyl-2-{2-[1-hexyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}propionicacid EC₅₀=0.213 μM

[0632]

2-Methyl-2-{2-[1-hexyl-3-(4-trifluoromethylsulfanylphenyl)ureido]indan-5-ylsulfanyl}propionicacid EC₅₀=0.123 μM

[0633]

2-Methyl-2-{2-[1-propyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}propionicacid EC₅₀=0.158 [M

[0634]

2-Methyl-2-{2-[1-butyl-3-(4-trifluoromethylsulfanylphenyl)ureido]indan-5-ylsulfanyl}propionicacid EC₅₀=0.160 μM

[0635]

2-Methyl-2-{2-[3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}propionicacid EC₅₀=0.135 μM

[0636]

2-Methy-2-{2-[1-pent-4-enyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}propionicacid EC₅₀=0.125 μM

[0637]

2-Methyl-2-{2-[1-(3-methylbutyl)-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid EC₅₀=0.106 μM

[0638]

2-{2-[3-(4-isopropylphenyl)-1-(3-methylbutyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid EC₅₀=0.106 μM

[0639]

2-{6-[1-Butyl-3-(4-trifluoromethoxyphenyl)ureido]-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid EC₅₀=0.219 μM

[0640]

2-{6-[1-Butyl-3-(4-trifluoromethylsulfanylphenyl)ureido]-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid EC₅₀=0.244 μM

[0641]

2-{6-[1-Hexyl-3-(4-trifluoromethoxyphenyl)ureido]-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid EC₅₀=0.235 μM

[0642]

2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-methoxy-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid EC₅₀=0.045 μM

[0643]

2-{6-[1-Ethyl-3-(4-trifluoromethoxy-phenyl)-ureido]-5,6,7,8-tetrahydro-naphthalen-2-yloxy}-2-methyl-propionicacid EC₅₀=0.309 μM

[0644]

2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-fluoro-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid EC₅₀=0.010 μM

[0645]

2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-chloro-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid EC₅₀=0.027 μM

[0646]

2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-bromo-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid EC₅₀=0.017 μM

[0647]

2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-methyl-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionic acid EC₅₀=0.042μM

[0648]

2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-trifluoromethoxy-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid EC₅₀=0.131 μM

[0649]

2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-phenyl-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid EC₅₀=0.545 μM

[0650]

2-{6-[1-Ethyl-3-(4-hydroxyphenyl)ureido]-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid

[0651]

2-{6-[4-Aminophenyl)-1-ethyl-ureido]-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid

[0652]

2-{3-Chloro-6-[(4-methyl-phenoxycarbonyl)-ethyl-amino]-5,6,7,8-tetrahydro-naphthalen-2-ylsulfanyl}-2-methyl-propionicacid EC₅₀=0.340 μM

[0653]

2-{3-Chloro-6-[(4-chloro-phenoxycarbonyl)-ethyl-amino]-5,6,7,8-tetrahydro-naphthalen-2-ylsulfanyl}-2-methyl-propionicacid EC₅₀=0.390 μM

[0654]

2-{6-[Ethyl-(4-trifluoromethoxy-phenoxycarbonyl)-amino]-5,6,7,8-tetrahydro-naphthalen-2-ylsulfanyl}-2-methyl-propionicacid EC₅₀=0.002 μM BIOLOGICAL EXAMPLE 1

[0655] HD bDNA Assay

[0656] H4IIE rat hepatoma cell line was obtained from ATCC. Cells werecultured in 175 cm² tissue culture flask or seeded in 96-well plate with(high serum content, 10% fetal bovine serum and 10% calf serum) culturemedium and maintained at 37° C. and 5% CO₂ throughout study. Twenty-fourhours after the initial seeding of the 96-well plate by hand(approximate 100,000/well), the HD gene induction assay was initiated.Media was removed and replaced with 100 ul of low serum culture media(5% charcoal/dextran treated calf serum) containing vehicle (DMSO) ortest compounds or standard. Cells returned to incubator for 24 hoursculture. At the termination of the challenge, 50 ul lysis buffer with HDgene specific CE, LE, BL probes was added directly into each well toinitiate the bDNA HD mRNA assay. The branched DNA assay was performedaccording to the manufacturer's protocol (Bayer Diagnostics; Emeryville.Calif.). At the end of the assay, the luminescence was quantitated inDynex MLX microtiter plate luminometer. EC₅₀'s were determined bynon-linear regression with a sigmoidal fit utilizing Graphpad Prism.

BIOLOGICAL EXAMPLE 2

[0657] Transfection Assay for PPAR₈ Receptors

[0658] HEK293 cells were grown in DMEM/F-12 Media supplemented with 10%FBS and glutamine (GIBCOBRL). The cells were co-transfected with DNA forPPAR-Gal4 receptor and Gal4-Luciferase Reporter using the DMRIE-CReagent. On the following day, the DNA-containing medium were replacedwith 5% Charcoal treated FBS growth medium. After six hours, cells wereseeded in 96well plate and incubated at 37° C. in CO₂ incubatorovernight. Cells were challenged by test compounds and incubated for 24hours at 37° C. in 5% CO₂ incubator. Luciferase activity was assayedusing the Steady-Glo Luciferase Assay Kit from Promega. DMRIE-C Reagentwas purchased from GIBCO Cat. No.10459-014. OPTI-MEM I Reduced SerumMedium was purchased from GIBCO Cat. No. 31985. Steady-Glo LuciferaseAssay Kit was obtained from Promega Part#E254B. In Vitro Data PPARαPPARδ FI*¹ PPARγ FI*² Example EC₅₀ (μM) [EC₅₀ (μM)] [EC₅₀ (μM)]  1 0.023 2 0.027 4.2  0.24  3 0.002 [>10] [>10]  4 0.037  3.7  5 0.053 2.5  4.0 6 0.056 3.6  1.9  7 0.075 0.8  0  8 0.073 5.9  1.9  9 0.131 1.0  2.9 100.165  5.1 11 0.173  6.1 12 0.183 11 13 0.184  1.2 14 0.213 1.3  0.3 150.123 1.2 16 0.158  0.37 17 0.160  0.43 18 0.135  0.31 19 0.125 1.4 200.106  0.44 21 0.106  0.05 22 0.219 23 0.244 24 0.235 25 0.208 4.5 260.130 2.1 27 0.294 28 0.323 8.2 29 0.382 30 0.385 31 0.497 32 0.497 1.533 0.537 0.8 34 0.657 35 0.772 5.6 36 0.796 37 0.838 1.9 38 0.950 391.00 9.3 40 1.30 41 2.21 42 2.34 43 2.99 44 2.09 45 0.780 46 1.39 6.0 470.045 [>3] 48 0.014 [>3] 49 0.309 [>3] 50 0.010 [>3] [>3] 51 0.027 [>10]52 0.017 [>3] 53 0.042 [0.873] 54 0.131 [>3] 55 0.545 [1.72] 58 0.340[0.613] [>3] 59 0.390 [0.655] [1.11] 60 0.002 [>3] [>3]

BIOLOGICAL EXAMPLE 3 aP2 Assay for PPAR Gamma Agonists

[0659] The procedure is described in detail in Burris et al., MolecularEndocrinology 99, 13:410, which is hereby incorporated by reference inits entirety, and aP2 assay results of agonist intrinsic activity may bepresented as fold increase over vehicle in induction of aP2 mRNAproduction.

[0660] Twenty-four hours after the initial seeding of the 96-well platesby hand (around 20,000/well), the differentiation assay may beinitiated. Medium may be removed and replaced with 150 μl ofdifferentiation medium containing vehicle (DMSO) or test compounds.Cells may be returned to incubator for 24 hours culture. At thetermination of the challenge, medium may be removed and 100 ul of lysisbuffer may be added to initiate the bDNA aP2 mRNA assay. The branchedDNA assay may be performed according to the manufacturer's protocol(Bayer Diagnostics; Emeryville, Calif.). Result may be expressed as thefold increase of aP2 RNA production activated over vehicle controls.EC₅₀'s and Emax may be determined by non-linear regression with asigmoidal fit curve.

[0661] Following the challenge of the preadipocytes, cells may be lysedwith lysis buffer (Bayer Diagnostics) containing the aP2oligonucleotides. After a 15 minute incubation at 53° C. or 30 minutesat 37° C. incubator, 70 ul of the lysis buffer from each well may beadded to a corresponding capture well (preincubated with 70 ul ofblocking buffer (Bayer Diagnostics)). The capture plate may be incubatedovernight at 53° C. in a plate incubator (Bayer Diagnostics). After thisincubation, the bDNA and labeled probes may be annealed as directed bythe manufacturer. Following a 30-minute incubation with the luminescentalkaline phosphatase substrate, dioxitane, the luminescence may bequantitated in a Dynex MLX microtiter plate luminometer. Oligonucleotideprobes designed to anneal to the aP2 mRNA and function in the bDNA mRNAdetection system are designed with ProbeDesigner software (BayerDiagnostics). This software package analyzes a target sequence ofinterest with a series of algorithms in order to determine which regionsof the sequence can perform as locations for capture, label, or spacerprobe annealing. The sequences of the oligonucleotides are as follows:CATTTTGTGAGTTTTCTAGGATTATTCTTTTCTCTTG SEQ ID NO.1 GAAAGAAAGTATGTTAGGTTTGGCCATGCCTTTCTCTTGGAAAGAAA SEQ ID NO.2 GTCCTCTCGTTTTCTCTTTATGGTTTTCTCTTGGAAAGA SEQ ID NO.3 AAGTGCTTATGCTCTCTCATAAACTCTCGTGGTTTCTCTTG SEQ ID NO.4 GAAAGAAAGTCCAGGTACCTACAAAAGCATCACATTTAGGCATAGGA SEQ ID NO.5 CCCGTGTCTGCCCACTCCTACTTCTTTCATATAATCATTTAGGCAT SEQ ID NO.6 AGGACCCGTGTCTAGCCACTTTCCTGGTGGCAAATTTAGGCATAGGACCC SEQ ID NO.7 GTGTCTCATCCCCATTCACACTGATGATCTTTAGGCATAGGAC SEQ ID NO.8 CCGTGTCTGTACCAGGACACCCCCATCTAAGGTTTTTAGGCATAG SEQ ID NO.9 GACCCGTGTCTGGTTGATTTTCCATCCCATTTCTGCACATTTTAGGCA SEQ ID NO.10 TAGGACCCGTGTCTGCATTCCACCACCAGTTTATCATTTTAGGCATAGGAC SEQ ID NO.11 CCGTGTCTGCGAACTTCAGTCCAGGTCAACGTCCCTTGTTTAGGC SEQ ID NO.12 ATAGGACCCGTGTCTTCCCACAGAATGTTGTAGAGTTCAATTTTAGGCATAG SEQ ID NO.13 GACCCGTGTCTAAAACAACAATATCTTTTTGAACAATATATTTAGGCA SEQ ID NO.14 TAGGACCCGTGTCTTCAAAGTTTTCACTGGAGACAAGTTT SEQ ID NO.15 AAAGGTACTTTCAGATTTAATGGTGATCASEQ ID NO.16 CTGGCCCAGTATGAAGGAAATCTCAGTATTTTT SEQ ID NO.17TCTGCAGTGACTTCGTCAAATTC SEQ ID NO.18 ATGGTGCTCTTGACTTTCCTGTCA SEQ IDNO.19 AAGTGACGCCTTTCATGAC SEQ ID NO.20

BIOLOGICAL EXAMPLE 4 11 Day Dosing of Example 3 in Female, 6-7 week Olddb/db Mice

[0662] (Female db/db mice (C57 BLK S/J−m+/+Lepr^(db), Jackson Labs, BarHarbor, Me.), 6-7 weeks of age, were housed four per cage insolid-bottomed shoe box cages. Room temperature was maintained at 68-72°F. and humidity at 50-65%. Room lighting was on a 12-hour light/12-hourdark cycle. Mice were fed a certified NIH Rat and Mouse/Auto 6F reducedfat diet #5K52 (P M I Nutrition Int'l, St. Louis, Mo., via W. F. Fisherand Son, Inc., Bound Brook, N.J.). Food and water were supplied adlibitum.

[0663] The compound was prepared as suspensions in 0.5%hydroxypropyl-methylcellulose (Dow Chemical, Midland, Mich.). The dosingvolume was 10 mL/kg of body weight. Female db/db diabetic mice (8/group)were orally gavaged once daily for 11 days with either 0.5%methylcellulose in dH₂O (vehicle) or PPARagonist at either 0.03, 0.1,0.3, 1, 3,10 mg/kg/day. Body weight was measured in the mornings on Day1, prior to dosing, and on Day 12 before bleeding. 18-24 hours after thefinal dose for each group, the mice were anesthetized with CO₂/O₂(70:30) and bled by retro-orbital sinus puncture into micro-tubescontaining clog activator and then put in ice. The serum samples wereprepared by centrifugation. Serum glucose and triglycerides weredetermined by using COBAS Mira Plus blood chemistry analyzer (RocheDiagnostics, N.J.). Serum insulin was measured by using ALPCO insulinELISA kit.

[0664] Statistical analysis was performed using the program Prism(Graphpad, Monrovia, Calif.) and performing one-way ANOVA with aDunnett's multiple comparison test. In Vivo data Example¹ Δ Plasma TG ΔPlasma Glucose Δ Plasma Insulin 1² −52% −73% −46% 2³ −56% −60% −53% 3⁴−66% −66% −69% 4⁴ −47% −49% −13% 5⁴ −19% −31% −43% 6⁴ −50% −49% −19% 7⁴−63% −44% −40% 8⁴ −27% −28% −38% 9⁴  −6% −13% −40%

BIOLOGICAL EXAMPLE 5 11 Day Dosing of Example in Female, 7 week Oldob/ob Mice

[0665] (Female ob/ob mice (C57 BL/6J Lep^(ob), Jackson Labs, Bar Harbor,Me.), 7 weeks of age, were housed two per cage in solid-bottomed shoebox cages. Room temperature was maintained at 68-72° F. and humidity at50-65%. Room lighting was on a 12-hour light/12-hour dark cycle. Micewere fed a certified NIH Rat and Mouse diet #5K50 (P M I NutritionInt'l, St. Louis, Mo., via W. F. Fisher and Son, Inc., Bound Brook,N.J.). Food and water were supplied ad libitum.

[0666] The compound was prepared as suspensions in 0.5%hydroxypropyl-methylcellulose (Dow Chemical, Midland, Mich.). The dosingvolume was 10 mL/kg of body weight. Female ob/ob diabetic mice (8/group)were orally gavaged once daily for 11 days with either 0.5%methylcellulose in dH₂O (vehicle) or PPAR agonist at 0.003, 0.01, 0.03,0.1, 0.3, 1 mg/kg/day. Body weight was measured in the mornings on Day1, prior to dosing, and on Day 12 before bleeding. 18 hours after thefinal dose for each group, the mice were anesthetized with CO₂/O₂(70%:30%) and bled by retro-orbital sinus puncture into micro-tubescontaining clog activator and then put in ice. The serum samples wereprepared by centrifugation. Serum glucose and triglycerides weredetermined by using COBAS Mira Plus blood chemistry analyzer (RocheDiagnostics, N.J.). Serum insulin and free fatty acids were measured byusing ALPCO insulin ELISA kit and Wako NEFA kit, respectively.

[0667] Statistical analysis was performed using the program Prism(Graphpad, Monrovia, Calif.) with one-way ANOVA and a Dunnett's multiplecomparison test. In Vivo data Δ Δ Δ Plasma Plasma Plasma Example¹ TGGlucose Insulin 50 −86% −74% −93%

[0668] E. Other Embodiments

[0669] The features and principles of the invention are illustrated inthe discussion, examples, and claims herein. Various adaptations andmodifications of the invention will be apparent to a person of ordinaryskill in the art and such other embodiments are also within the scope ofthe invention. Publications cited herein are incorporated in theirentirety by reference.

1 20 1 47 DNA Homo sapiens 1 cattttgtga gttttctagg attattcttt tctcttggaaagaaagt 47 2 39 DNA Homo sapiens 2 atgttaggtt tggccatgcc tttctcttggaaagaaagt 39 3 41 DNA Homo sapiens 3 cctctcgttt tctctttatg gttttctcttggaaagaaag t 41 4 47 DNA Homo sapiens 4 gcttatgctc tctcataaac tctcgtggtttctcttggaa agaaagt 47 5 46 DNA Homo sapiens 5 ccaggtacct acaaaagcatcacatttagg cataggaccc gtgtct 46 6 50 DNA Homo sapiens 6 gcccactcctacttctttca tataatcatt taggcatagg acccgtgtct 50 7 43 DNA Homo sapiens 7agccactttc ctggtggcaa atttaggcat aggacccgtg tct 43 8 45 DNA Homo sapiens8 catccccatt cacactgatg atctttaggc ataggacccg tgtct 45 9 48 DNA Homosapiens 9 gtaccaggac acccccatct aaggttttta ggcataggac ccgtgtct 48 10 51DNA Homo sapiens 10 ggttgatttt ccatcccatt tctgcacatt ttaggcataggacccgtgtc t 51 11 45 DNA Homo sapiens 11 gcattccacc accagtttatcattttaggc ataggacccg tgtct 45 12 52 DNA Homo sapiens 12 gcgaacttcagtccaggtca acgtcccttg tttaggcata ggacccgtgt ct 52 13 48 DNA Homo sapiens13 tcccacagaa tgttgtagag ttcaatttta ggcataggac ccgtgtct 48 14 51 DNAHomo sapiens 14 aaaacaacaa tatctttttg aacaatatat ttaggcatag gacccgtgtc t51 15 26 DNA Homo sapiens 15 tcaaagtttt cactggagac aagttt 26 16 29 DNAHomo sapiens 16 aaaggtactt tcagatttaa tggtgatca 29 17 33 DNA Homosapiens 17 ctggcccagt atgaaggaaa tctcagtatt ttt 33 18 23 DNA Homosapiens 18 tctgcagtga cttcgtcaaa ttc 23 19 24 DNA Homo sapiens 19atggtgctct tgactttcct gtca 24 20 19 DNA Homo sapiens 20 aagtgacgcctttcatgac 19

1. A compound of Formula I

or a pharmaceutically acceptable salt, C 1e ester or C 16 amide thereof,wherein each of R₁ and R₂ is independently H, C 16 alkyl,(CH₂)_(m)NR_(a)R_(b), (CH₂)_(m)OR₈, (CH₂)_(m)NH(CO)R₈, or(CH₂)_(m)CO₂R₈, where each of R_(a), R_(b), and R₈ is independently H orC 1e alkyl, or R₁ and R₂ taken together with the carbon atom to whichthey are attached are a C₃₋₇ cycloalkyl; m is between 1 and 6; n is 1 or2; X is O or S; wherein X is at the 5 or 6 position when n is 1; andwherein X is at the 6 or 7 position when n is 2; R₃ is H, phenyl, C₁₋₃alkoxy, C₁₋₃ alkylthio, halo, cyano, C₁₋₆ alkyl, nitro, NR₉R₁₀, NHCOR₁₀,CONHR₁₀; and COOR₁₀; and R₃ is ortho or meta to X; R₄ is H or —(C₁₋₅alkylene)R₁₅, where R₁₅ is H, C₁₋₇ alkyl, [di(C₁₋₂ alkyl)amino](C₁₋₆alkylene), (C₁₋₃ alkoxyacyl)(C₁₋₆ e alkylene), C₁₋₆ alkoxy, C₃₋₇alkenyl, or C₃₋₈ alkynyl, wherein R₄ has no more than 9 carbon atoms; R₄can also be —(C₁₋₅ alkylene)R₁₅ wherein R₁₅ is C 36 cycloalkyl, phenyl,phenyl-O—, phenyl-S—, or a 5-6 membered heterocyclyl with between 1 and2 heteroatoms selected from N, O, and S; Y is NH, NH—CH₂, and O; each ofR₅ and R₇ is independently selected from H, C 1-6 alkyl, halo, cyano,nitro, COR₁₁, COOR₁₁, C₁₋₄ alkoxy, C₁₋₄ alkylthio, hydroxy, phenyl,NR₁₁R₁₂ and 5-6 membered heterocyclyl with between 1 and 2 heteroatomsselected from N, O, and S; R₆ is selected from C₁₋₆ alkyl, halo, cyano,nitro, COR₁₃, COOR₁₃, C₁₋₄ alkoxy, C₁₋₄ alkylthio, hydroxy, phenyl,NR₁₃R₁₄ and 5-6 membered heterocyclyl with between 1 and 2 heteroatomsselected from N, O, and S; in addition, either R₅ and R₆ or R₆ and R₇may be taken together to be a bivalent moiety, saturated or unsaturated,selected from —(CH₂)₃—, —(CH₂)₄—, and (CH₁-₂)_(p)N(CH, ₂)_(q), p is 0-2and q is 1-3, where the sum (p+q) is at least 2; each of R₉ and R₁₀ isindependently C₁₋₆ alkyl; each of R₁₁, R₁₂, R₁₃ and R₁₄ is independentlyH or C₁₋₆ alkyl; wherein each of the above hydrocarbyl and heterocarbylmoieties may be substituted with between 1 and 3 substituentsindependently selected from F, Cl, Br, I, amino, methyl, ethyl, hydroxy,nitro, cyano, and methoxy.
 2. A compound of claim 1, wherein one of R₁and R₂ is methyl or ethyl.
 3. A compound of claim 2, wherein each of R₁and R₂ is methyl.
 4. A compound of claim 1, wherein R₁ and R₂ takentogether are cyclobutyl or cyclopentyl.
 5. A compound of claim 1,wherein R₃ is H.
 6. A compound of claim 1, wherein R₃ is C₁₋₃ alkoxy,C₁₋₃ alkylthio, halo, cyano, C₁₋₆ alkyl, nitro, NR₉R₁₀, NHCOR₁₀,CONHR₁₀; or COOR₁₀.
 7. A compound of claim 1, wherein R₄ is H or C₂₋₇alkyl.
 8. A compound of claim 7, wherein R₄ is H or C₂₋₅ alkyl.
 9. Acompound of claim 8, wherein R₄ is ethyl.
 10. A compound of claim 8,wherein R₄ is H.
 11. A compound of claim 1, wherein n is
 1. 12. Acompound of claim 1, wherein n is
 2. 13. A compound of claim 1, whereinY is NH—CH₂.
 14. A compound of claim 1, wherein Y is NH.
 15. A compoundof claim 1, wherein X is S.
 16. A compound of claim 1, wherein X is O.17. A compound of claim 1, wherein at least one of R₅ and R₇ is H.
 18. Acompound of claim 17, wherein R₆ is C₁₋₄ alkyl, halomethoxy,halomethylthio, or di(C₁₋₃ alkyl)amino.
 19. A compound of claim 18,wherein R₆ is trifluoromethoxy, difluoromethoxy, trifluoromethyl,trifluoromethylthio, t-butyl, isopropyl, or dimethylamino.
 20. Acompound of claim 3, wherein R₃ is H, R₄ is C₂₋₇ alkyl, and Y is NH. 21.A compound of claim 20, wherein X is S.
 22. A compound of claim 20,wherein n is
 1. 23. A compound of claim 20, wherein n is
 2. 24. Acompound of claim 20, wherein R₄ is C₂₋₅ alkyl.
 25. A compound of claim24, wherein R₄ is ethyl.
 26. A compound of claim 20, wherein R₆ istrifluoromethoxy, difluoromethoxy, trifluoromethyl, trifluoromethylthio,t-butyl, isopropyl, or dimethylamino.
 27. A compound of claim 1, whereineach of R₁ and R₂ is independently H, C₁₋₆ alkyl, (CH₂)_(m)NR_(a)R_(b),or (CH₂)_(m)OR₈, where each of R_(a), R_(b), and R₈ is independently Hor C₁₋₆ alkyl; m is between 1 and 6; n is 1 or 2; X is O or S; wherein Xis at the 5 or 6 position when n is 1; and wherein X is at the 6 or 7position when n is 2; R₃ is H, phenyl, C₁₋₃ alkoxy, C₁₋₃ alkylthio,halo, C₁₋₆ alkyl, or NR₉R₁₀, and R₃ is ortho or meta to X; R₄ is H or—(C₁₋₅ alkylene)R₁₅, where R₁₅ is H c, C₇ alkyl, [di(C₁₋₂alkyl)amino](C₁₋₆ alkylene), (C₁₋₃ alkoxyacyl)(C₁₋₆ alkylene), C₁₋₆alkoxy, or C₃₋₇ alkenyl, wherein R₄ has no more than 9 carbon atoms; R₄can also be —(C₁₋₅ alkylene)R₁₅ wherein R₁₅ is C₃₋₆ cycloalkyl, phenyl,phenyl-O—, phenyl-S—, or a 5-6 membered heterocyclyl with between 1 and2 heteroatoms selected from N, O, and S; Y is NH or NHCH₂; each of R₅and R₇ is independently selected from H, C₁₋₆ alkyl, halo, COR₁₁,COOR₁₁, C₁₋₄ alkoxy, C₁₋₄ alkylthio, hydroxy, and NR₁₁R₁₂; R₆ isselected from C₁₋₆ alkyl, halo, COR₁₃, COOR₁₃, C₁₋₄ alkoxy, C₁₋₄alkylthio, phenyl, NR₁₃R₁₄ and 5-6 membered heterocyclyl with between 1and 2 heteroatoms selected from N, O, and S; each of R₉ and R₁₀ isindependently C₁₋₆ alkyl; each of R₁₁, R₁₂, R₁₃ and R₁₄ is independentlyH or C₁₋₆ alkyl; wherein each of the above hydrocarbyl and heterocarbylmoieties may be substituted with between 1 and 3 substituentsindependently selected from F, Cl, amino, methyl, ethyl, hydroxy, andmethoxy.
 28. A compound of claim 1, selected from:2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionic acid;2-{2-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid;2-{2-[1-Ethyl-3-(4-trifluoromethylsulfanylphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid;2-Methyl-2-{2-[1-pentyl-3-(4-trifluoromethylsulfanylphenyl)ureido]indan-5-ylsulfanyl}propionicacid; 2-{2-[1-Ethyl-3-(4-isopropylphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionic acid;2-Methyl-2-{2-[1-pentyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid;2-{2-[3-(4-Dimethylaminophenyl)-1-ethylureido]indan-5-ylsulfanyl}-2-methylpropionicacid;2-Methyl-2-{2-[1-(3-methylbutyl)-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid;2-{2-[3-(4-Isopropylphenyl)-1-(3-methylbutyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid;2-Methy-2-{2-[1-pent-4-enyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}propionicacid;2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-methoxy-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid; 2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-fluoro-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionic acid;2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-chloro-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid;2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-bromo-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid;2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-methyl-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid; and2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-trifluoromethoxy-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid.
 29. A compound of claim 1, selected from2-Methyl-2-{2-[1-hexyl-3-(4-trifluoromethylsulfanylphenyl)ureido]indan-5-ylsulfanyl}propionicacid;2-{2-[3-(4-Dimethylaminophenyl)-1-pentylureido]indan-5-ylsulfanyl}-2-methylpropionicacid;2-Methyl-2-{2-[3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}propionicacid;2-Methyl-2-{2-[1-propyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}propionicacid;2-Methyl-2-{2-[1-butyl-3-(4-trifluoromethylsulfanylphenyl)ureido]indan-5-ylsulfanyl}propionicacid;2-{2-[3-(4-Isopropylphenyl)-1-(3-pentyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid;2-{2-[3-(4-tert-Butylphenyl)-1-(3-pentyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid; 2-[2-(3-(Biphenyl-4-yl-1-pentylureido)indan-5-ylsulfanyl]-2-methylpropionic acid;2-{2-[3-(4-Isopropylphenyl)-1-(3-hexyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid;2-Methyl-2-{2-[1-butyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}propionicacid;2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-methoxy-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid;2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-fluoro-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid;2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-chloro-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid;2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-bromo-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid; 2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-methyl-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionic acid; and2-Methyl-2-{2-[1-hexyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}propionicacid.
 30. A compound of claim 1, selected from:2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid;2-{6-[3-(4-Trifluoromethoxyphenyl)ureido]-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid;2-{2-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid; 2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-fluoro-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionic acid;2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-methyl-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionicacid;2-{2-[1-Ethyl-3-(4-trifluoromethylsulfanylphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid; and2-Methyl-2-{2-[1-propyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}propionicacid.
 31. A compound of claim 1, selected from:2-{2-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid;2-{2-[1-Ethyl-3-(4-trifluoromethylsulfanylphenyl)ureido]indan-5-ylsulfanyl}-2-methylpropionicacid;2-Methyl-2-{2-[1-propyl-3-(4-trifluoromethoxyphenyl)ureido]indan-5-ylsulfanyl}propionicacid; and 2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-3-fluoro-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionic acid.
 32. Apharmaceutical composition, comprising a compound of claim 1, 20, 27,28, 30, or
 31. 33. A method for treating or inhibiting the progressionof a PPAR-alpha mediated disease, said method comprising administeringto a patient in need of treatment a pharmaceutically-effective amount ofa composition comprising a compound of claim 1, 20, 27, 28 or 31,wherein said PPAR-alpha mediated disease is selected from impairedglucose tolerance, hyperinsulinemia, hyperglycemia, insulin resistance,and early, intermediate or late Type II diabetes (NIDDM), andcomplications thereof.
 34. A method of claim 33, wherein saidcomplication is selected from retinopathy, nephropathy, and neuropathy.35. A method of claim 33, wherein said PPAR-alpha mediated disease isselected from impaired glucose tolerance, insulin resistance,hyperglycemia, hyperinsulinemia, and early Type II diabetes, andcomplications thereof.
 36. A method of claim 33, wherein said PPAR-alphamediated disease is selected from intermediate or late Type II diabetes,and complications thereof.
 37. A method of claim 33, wherein saidcompound of claim 1, 20, 27, 28, or 31 is a first anti-diabetic agent,and wherein said method further comprises the step of administering tothe patient a jointly-effective amount of a second anti-diabetic agent.38. A method of claim 37, wherein said second anti-diabetic agent isselected from PPAR alpha and PPAR gamma modulating agents.
 39. A methodof claim 37, wherein said second anti-diabetic agent is insulin.
 40. Amethod of claim 33, further comprising the step of administering ajointly-effective amount of a third pharmaceutically active agent.
 41. Amethod of claim 40, wherein said third pharmaceutically active agent isselected from an anti-diabetic agent, a lipid lowering agent, and ablood-pressure lowering agent.
 42. A method both for treating orinhibiting the progression of a PPAR-alpha mediated disease and fortreating or inhibiting the progression of dyslipidemia, said methodcomprising administering to a patient in need of treatment apharmaceutically-effective amount of a composition comprising a compoundof claim 1, 20, 27, 28 or 31, wherein said PPAR-alpha mediated diseaseis selected from impaired glucose tolerance, hyperinsulinemia, insulinresistance, and early, intermediate or late Type II diabetes (NIDDM),and complications thereof.
 43. A method of claim 42, wherein saidcomposition consists essentially of a compound of claim 1, 20, 27, 28,or 31.